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ABSTRACT 
Parkinson's disease (PO) is misdiagnosed throughout its disease course for 
conditions such as essential tremor, drug-induced parkinsonism, vascular pseudo-
parkinsonism, Alzheimer's disease and other degenerative parkinsonian diseases. 
Functional brain dopaminergic imaging (e.g. with [1231) FP-CIT SPECT) is used to 
distinguish degenerative parkinsonism from essential tremor where it is known to be 
accurate in established disease. Less is known about its accuracy in early disease or 
for distinguishing PO from its other non-degenerative parkinsonian/ tremor mimics. A 
minority with clinically diagnosed PO have normal dopaminergic imaging. 
This thesis aims to verify the accuracy of dopaminergic imaging in early and 
uncertain parkinsonian/ tremor disorders through 3 studies. The first is a prospective 
United Kingdom multicentre assessment of [123 1) FP-CIT SPECT use in 190 patients 
in pre-defined diagnostic categories and with particular focus on clinical features to 
assess the influence of imaging in routine practice. The second is a 2 year follow-up 
study of 150 consecutive patients with normal SPECT, with specific attention to 
clinical progression and antiparkinson medication use, and includes focus on a 
subgroup who fulfilled PO criteria where successful anti parkinson medication 
withdrawal was achieved. The third is a multicentre prospective European study of 
the accuracy of [123 1) FP-CIT SPECT in 99 patients that included serial clinical and 
imaging assessments. 
Notably, when initial diagnosis/ scan mismatch cases occurred, and with awareness 
of the scan result, the clinician invariably changed the diagnosis in line with the scan 
result which confirms the considerable influence of imaging on the practising 
clinician. Parkinson's disease is clinically overdiagnosed early in its disease course, 
11 
whereas imaging is more specific. In the vast majority of cases with normal 
dopaminergic imaging, there was no evidence of clinical or imaging progression 
which would be in keeping with degenerative parkinsonism. 
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Summary 
The clinical diagnosis of Parkinson's disease (PD) and differentiation from some of its 
parkinsonian/ tremor mimics is often straightforward but misdiagnosis does occur, 
even in late stage disease. Misdiagnosis leads to inappropriate treatment, (with 
potential morbidity from treatment side-effects or even lack of treatment), incorrect 
prognostic advice (in some cases lack of recognition of a potentially reversible 
disorder) and there are additional concerns over inappropriate placement of patients 
without Parkinson's disease into PD studies. 
A number of adjuncts to improve the clinical diagnosis are under scrutiny, including 
radioisotope imaging of the brain dopaminergic neurone. In particular, radiolabelling 
the presynaptic dopaminergic neurone with ligands such as 1231-N-fluropropyl-2 [1-
carbomethoxy-3 [1-(4-iodophenyl)nortropane ([1231] FP-CIT) is an accurate method to 
differentiate patients with established Parkinson's disease from those with essential 
tremor. It can differentiate Parkinson's disease from disorders without disruption of 
the presynaptic dopaminergic neurones (such as essential tremor or drug-induced 
parkinsonism) but cannot differentiate between Parkinson's disease and other types 
of degenerative parkinsonism. Little is known about its precision or usefulness in 
early uncertain Parkinson's disease and its parkinsonian mimics. 
The aim of this thesis is to investigate the utility and accuracy of [1231] FP-CIT SPECT 
in early and uncertain parkinsonian conditions. 
In the introduction (Chapter 1), a review of the differential diagnosis of Parkinson's 
disease and clinical diagnostic accuracy is followed by a description of the tools 
available or being developed as an adjunct to clinical acumen. There then follows a 
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review of functional dopaminergic brain imaging and current knowledge on the 
accuracy of imaging of the presynaptic neurone. 
The UK Case Collection Study was a large prospective study of the current use of 
[1231] FP-CIT SPECT in uncertain parkinsonism in routine clinical practice (Chapters 
2, 3 and 4). There were pre-specified diagnostic pairings with prospective 
documentation of clinical features and diagnoses. The aim was to identify differences 
in rates of concurrence of initial uncertain diagnosis, SPECT result and post-scan 
diagnoses with reference to the cardinal features of parkinsonism. 
Chapter 1 gives an overview of all 190 subjects within the study where an overall, 
unexpected scan result (according to pre-scan uncertain diagnosis) occurred in 
around one-quarter of patients. There were more unexpected scan results within 
subjects labelled initially as vascular parkinsonism than in other categories, 
suggesting more clinical diagnostic difficulty within this group. Up to 40% of patients 
fulfilling basic criteria for PO had normal imaging. SPECT visual assessment gave a 
clear answer of normal or abnormal in 97%. Chapter 3 considers in detail the utility of 
[1231] FP-CIT SPECT in differentiating between uncertain tremor disorders and 
Chapter 4 focuses on subjects with parkinsonism associated with drug use. 
The issue of whether evidence of degenerative parkinsonism may emerge over time 
in subjects with normal [1231] FP-CIT SPECT is considered in 2 follow-up studies in 
Chapter 5. A 2 year follow-up in 150 consecutive cases with normal dopamine 
transporter imaging concluded that there was no evidence of clinical deterioration or 
response to antiparkinson therapy, and thus there was no indication of emerging 
degenerative parkinsonism. The vast majority of this series had diagnoses of non-
degenerative parkinsonism/ tremor conditions. In the second study, successful 
anti parkinson therapy withdrawal in 11 subjects who had suspected Parkinson's 
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disease but who had normal [123 1] FP-CIT SPECT was achieved without clinical 
deterioration after follow-up. 
The accuracy of [1231] FP-CIT SPECT to differentiate between early uncertain 
parkinsonism/ tremor disorders is examined within the blinded prospective European 
3 year follow-up study of 99 patients in Chapter 6. Imaging was repeated at 3 time 
points and a very high interrater agreement was found for visual assessment of 
SPECT for abnormal or normal. Evidence of clinical over-diagnosis of PO at baseline 
was identified. Specificity of baseline imaging was 97% with a lower sensitivity of 
78%. Fifteen of 71 subjects (21 %) with a 3 year diagnosis of Parkinson's disease had 
normal baseline imaging. Imaging remained repeatedly normal in all but 1 case. 
These subjects had no significant change in clinical rating scores, which 
differentiated these cases from patients with PO and abnormal SPECT. 
In summary, visual inspection of [1231] FP-CIT SPECT in subjects with uncertain 
parkinsonian conditions gives clear results in most cases, with good agreement 
between SPECT readers of the scans' result. In routine clinical practice, there is an 
unexpected scan result according to initial uncertain diagnosis in a quarter of cases. 
The influence of the SPECT scan is notable, as a change in diagnosis was made in 
most mismatch cases in line with the scan result. Up to 40% of patients fulfilling 
basic Parkinson's disease criteria have normal imaging, and long term follow-up of 
these cases finds no evidence of emerging parkinsonian disorders and anti parkinson 
therapy can be withdrawn successfully. Clinicians overdiagnose PO, but high 
specificity for baseline [1231] FP-CIT SPECT suggests that combining clinical and 
imaging assessments could reduce overdiagnosis of PO at an early stage. [1231] FP-
CIT SPECT gave normal results in a proportion of patients given a PO diagnosis 3 
years later. We found evidence within this group with normal scans of a different 
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clinical and imaging progression to those who definitely have PO, suggesting either a 
different form of PO or a non-PO diagnosis. 
In conclusion, [123 1] FP-CIT SPECT imaging will not replace clinical acumen but can 
be used as an adjunct to clinical diagnosis and has marked diagnostic influence in 
routine clinical practice. The clinician should be wary of a subject suspected to have 
PO who has a normal [1231] FP-CIT SPECT as we have provided evidence that this 
group has a lack of clinical and imaging progression, and a poor anti parkinson 
therapy response. 
XIX 
Chapter 1 : Introduction 
1 
1. Clinical diagnosis and differential diagnosis of parkinsonism 
The misdiagnosis of Parkinson's disease and its parkinsonian mimics 
The term 'parkinsonism' is a description of the clinical features of bradykinesia, 
accompanied by one or more of rigidity, postural instability or resting tremor. 
Parkinsonism results from idiopathic Parkinson's disease (PO) as well as other 
neurodegenerative disorders, cerebrovascular disease and can also be drug-
induced. Clinical diagnosis of parkinsonism is quite often straightforward and 
additional investigations are often not required. However, clinicopathological 
correlation in patients diagnosed in life with idiopathic Parkinson's disease shows 
that 10 - 25% have alternative diagnoses. Applying diagnostic criteria increases 
accuracy but reduces sensitivity, which can affect management of the individual 
case(1-5}. Eight percent (65 of 800) patients entered into a trial of a possible 
neuroprotective drug by movement disorder specialists with a diagnosis of early 
Parkinson's disease were found to have alternative diagnoses after 7.6 years of 
follow-up(6}. A community study in London found 15% (15/1 OO) of patients with a 
diagnosis of Parkinson's disease were misdiagnosed according to strict diagnostic 
criteria and detailed neurology review with follow-up(7}. Another study in North Wales 
confirmed a diagnosis of parkinsonism in 74% (299/402) and clinically probable 
Parkinson's disease in only 53% (213/402) of patients receiving anti parkinsonian 
medication(8}. It is in the early or atypical or overlap disorders that further 
investigations are necessary to improve clinical diagnostic certainty. Investigations 
such as structural or functional cranial imaging or drug challenge tests are most 
commonly employed. 
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Progressive supranuclear palsy (PSP), multiple system atrophy (MSA), Alzheimer's 
disease (AD) and vascular parkinsonism (VP) were most commonly misdiagnosed as 
Parkinson's disease in hospital based practice whereas in the community, essential 
tremor (ET), Alzheimer's disease and vascular parkinsonism were commoner(8) as 
diagnostic errors. Patients on neuroleptics were excluded from many of these 
studies. Despite the exclusion of obvious cases of drug-induced parkinsonism, 3% of 
cases with parkinsonism in the North Wales study were finally considered to have 
drug-induced parkinsonism(8). Other causes of parkinsonism such as 
hydrocephalus, Wilson's disease, intracerebral tumour or akinetic-rigid presentations 
of Huntington's are rare but may need to be considered. 
Strict classification schemes based on the presence of clinical features of 
parkinsonism exist and are useful particularly in clinical trials or studies (see Brain 
Bank criteria part 1 below), but in the clinical setting the presence of parkinsonism 
itself can be uncertain (e.g. in the presence of only limited bradykinesia or other 
'partial' fulfilment of the criteria, e.g. when there is only one of the following: reduced 
arm swing, mild slowing of finger taps, reduced facial expression or cogwheeling). 
The term 'uncertain parkinsonism' refers to a lack of confidence of either the 
presence of true parkinsonism or of the underlying cause. Understanding the 
potential causes of this is imperative for the accurate differentiation of PO from other 
disorders, including those traditionally not associated with parkinsonism such as 
essential tremor. 
The importance of an accurate diagnosis 
A correct initial diagnosis is important, as is monitoring and reconsideration of the 
correct diagnosis over time. Prognosis varies from one condition to another. 
Essential tremor is believed to give no change in life expectancy but previous beliefs 
of low disability have been questioned, particularly among those seeking specialist 
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advice(9). Parkinson's disease causes functional impairment in most patients and 
probably reduces life expectancy(1 0). Drug management varies, with potential for 
secondary prevention in stroke disease where there is vascular parkinsonism and 
withdrawal of offending medication in drug-induced parkinsonism. The potential harm 
from reversal of an initial incorrect diagnosis and accompanying removal of support 
services should preferably be avoided. 
1a) Parkinson's disease and other causes of degenerative parkinsonism 
Degenerative parkinsonism is a term used to encompass Parkinson's disease, 
multiple system atrophy, progressive supranuclear palsy and corticobasal 
degeneration (CBD). All syndromes may share similar features but each have distinct 
pathologies. The terms atypical parkinsonism or "Parkinson Plus" are used by some 
to describe MSA, PSP and CBD. 
Parkinson's disease 
Parkinson's disease is now considered more of a syndrome due to a number of both 
genetic and environmental factors. It has a prevalence of 1.6% in a European 
study(11) and does not seem to vary much worldwide. It is the most common cause 
of parkinsonism in the population(12;13) or referred to hospital neurology clinics(14), 
although drug-induced parkinsonism may be more common in certain settings such 
as geriatric department referrals(15). 
Parkinson's disease typically presents with unilateral 4 - 6 Hz resting tremor and 
stiffness in one limb, which progresses over time usually to affect all limbs but 
typically with retained predominance for the side of onset, and 'asymmetry' between 
the upper and lower limbs with the arms being involved to the greater extent(16). In 
some cases, as the disease progresses, the side of predominance may change, or 
rest tremor may become less pronounced(17). It is the motor symptoms that usually 
attract medical attention although the disorder commonly affects the sensory and 
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autonomic systems as well as cognition, sleep and emotion(18). Of 100 cases with 
histologically confirmed Parkinson's disease, mean disease onset was 62.4 (S.D. 
9.2) years, asymmetry was present in 72% and upper limbs alone were involved in 
65%, with tremor in 69%. Levodopa was commenced a mean of 3.2 years after first 
symptoms were noted(19). In a retrospective study of 253 patients with a clinical 
diagnosis of Parkinson's disease, tremor was the presenting complaint in 63%, and 
the tremor spread to the leg on the same side between 0.8 and 1.4 years from onset, 
and spread to the contralateral side after 2.1 to 3.4 years(20). Parkinson's disease 
may present atypically, for example with asymmetrical long duration postural 
tremor(21) or foot dystonia(22). 
The characteristic loss of dopaminergic neurons and formation of Lewy bodies within 
the remaining degenerating nigral neuronesis actually the third stage in a proposed 
staging system(23). Lewy bodies are found within the dorsal motor nucleus of the 
glossopharyngeal and vagal neurones and anterior olfactory nucleus in earlier 
disease(23). Nigral dopaminergic neurones project to the putamen and caudate 
(corpus striatum) and after a loss of 50 - 80%(24;25) a patient becomes 
symptomatic. More severe neurone loss occurs within the ventrolateral tier of the 
substantia nigra(26). Neurones project to the putamen from the ventral tier(27). Post-
mortem of Parkinson's disease patients finds a loss of presynaptic dopaminergic 
neurones which is more pronounced in the dorsal and caudal parts of the 
putamen(28). 
The direct mean annual cost per patient is £5,993 for all patients, calculated in 1998 
in the United Kingdom(29) which increases with age and disease severity. 
The retrospective application of recommended diagnostic criteria(30) improved the 
diagnostic accuracy of a post-mortem diagnosis of Parkinson's disease from 76% (for 
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a diagnosis made in life by neurologists or geriatricians) to 82%(1). These criteria 
follow 3 steps. 
• Step 1 requires the presence of bradykinesia plus one of rigidity, 4 - 6 Hz rest 
tremor and postural instability not caused by primary visual, vestibular, 
cerebellar or proprioceptive dysfunction. The requirement of the presence of 
bradykinesia eliminates cases of essential tremor with cogwheeling which 
would satisfy less strict criteria. 
• Step 2 excludes any patient with a history of repeated strokes with stepwise 
progression of parkinsonian features, repeated head injury, definite 
encephalitis, oculogyric crises, neuroleptic treatment at onset of symptoms, 
more than one affected relative, sustained remission, strictly unilateral 
features after 3 years, supranuclear gaze palsy, cerebellar signs, early severe 
autonomic involvement, early severe dementia, presence of the babinski sign, 
presence of cerebral tumour or communicating hydrocephalus on CT scan, 
negative response to large disease of levodopa and MPTP exposure. 
• Step 3 refers to supportive prospective positive criteria for Parkinson's 
disease (3 or more required for a diagnosis of definite Parkinson's disease). 
These are unilateral onset, presence of a rest tremor, a progressive disorder, 
persistent asymmetry affecting the side of onset most. Excellent response (70 
- 100%) to levodopa, severe levodopa induced chorea, levodopa response for 
5 years or more and a clinical course of 10 years or more(30). 
Application of further multiple criteria improves the specificity and positive predictive 
value for an PO diagnosis but to the detriment of excluding 32% of pathologically 
confirmed cases of PO(31). An identical study a decade later found that the accuracy 
of a PO diagnosis was 90%, and increased only slightly to 92% by the retrospective 
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application of Brain Bank criteria(32). These criteria can not be applied comparably 
in other settings, for example in early disease. 
Multiple system atrophy (MSA), progressive-supranuclear palsy (PSP) and 
corticobasal degeneration (CBO) 
They are all most often sporadic adult onset neurodegenerative disorders with 
distinct neuropathology (MSA is an alpha-synucleinopathy whilst PSP and CBD are 
regarded as tauopathies). All may respond to levodopa at least partially in the initial 
stages but are usually considered as levodopa-unresponsive conditions, and all can 
have overlapping features with Parkinson's disease or other neurodegenerative 
disorders for which they sometimes misdiagnosed. Clinical criteria exist, although not 
all have pathological verification and their sensitivity early in disease is poor(33). 
Multiple system atrophy 
Multiple system atrophy is currently classified according to whether patients 
demonstrate primarily parkinsonism (MSA-P) or cerebellar (MSA-C) features. 
Previously these were known as striatonigral degeneration or sporadic 
olivopontocerebellar degeneration respectively and a third type (Shy-Drager) has 
been described in those with primarily autonomic features. The newer classification 
takes into account the fact that the same pathology is found in all subtypes, and 
autonomic features may be prominent in either MSA-P or MSA-C. Pathologically 
there is gliosis and neuronal loss and alpha-synuclein positive oligodendroglial 
cytoplasmic inclusions within the striatum, substantia nigra, inferior olives, pons and 
cerebellum, intermediolateral cell columns and Onuf's nucleus within the spinal 
cord(34). 
The prevalence of MSA in London is 4.4 per 100,000 although this is likely to be an 
underestimate(35). Apart from parkinsonism, cerebellar or autonomic disturbances, 
red flag features include early restriction to a wheelchair (the 'wheelchair' sign), 
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irregular jerky postural and action tremor with jerkiness being due to stimulus 
sensitive myoclonus, rapid disease progression, and disturbances of the peripheral 
microcirculation with cold, dusky, violaceous extremities, sleep apnoea, stridor, 
involuntary inspiratory sighs or gasps during the day. Speech may be quite distinctive 
with a quivery croaky strained element. Emotional incontinence and REM sleep 
behaviour disorder are common but not specific. Dementia is unusual. Dystonia 
unrelated to levodopa may be found with camptocormia in some. A 
clinicopatholological study found that 8 of 59 (14%) patients with final diagnosis of 
MSA had alternative diagnoses, most commonly PO (6), PSP (1) and 
cerebrovascular disease (1)(36). 
Progressive supranuclear palsy (PSP or Steele-Richardson-Olszewski syndrome) 
The typical clinical features of progressive supranuclear palsy include early postural 
instability often with backwards falls, a fixed stare with markedly reduced blinking, 
and a fixed retracted neck with retrocollis. Impaired vertical gaze and early difficulties 
with swallowing combine to cause problems with spilling of food onto clothes (the 
'messy-tie' sign). A sub-cortical cognitive deficit often exists. PSP is characterised by 
the destruction of a number of sub-cortical structures including the substantia nigra, 
globus pallid us, subthalamic nucleus and midbrain and pontine reticular formation 
where neurofibrillary tangles, neuropil threads and tufted astrocytes are found. These 
inclusions are made from insoluble aggregates of tau phosphoprotein. Tau-positive 
glial inclusions are also present. A neuro-pathological study found 43 of 180 (24%) 
referred with a diagnosis of PSP actually had other diagnoses including corticobasal 
degeneration, multiple system atrophy and dementia with Lewy bodies(37). A 
prevalence of 1.39 to 14.3 per 100,000 has been found(38). The median duration 
from disease onset to death is 5.8 to 5.9 years(39). 
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Corticobasal degeneration (CBD) 
The core clinical features are of asymmetrical rigidity and apraxia together with other 
findings of cortical dysfunction such as sensory loss, alien limb phenomenon or 
myoclonus. Pathologically asymmetrical frontoparietal cortical atrophy with basal 
ganglia and nigral degeneration is found, there are ballooned, achromatic neurones 
found within the cortex and abnormal collections of tau protein within the neurones 
and glia. The main differential diagnosis of CBD includes Parkinson's disease, 
multiple system atrophy and progressive supranuclear palsy. Rarely, Alzheimer's 
disease can present in a similar fashion. 
1 b) Essential tremor 
This is the most common type of tremor with a quoted prevalence of 300 to 415 per 
100,000(40). 
This figure is likely to be unreliable, as only a minority of patients seek medical 
advice. Typically,. it is a bilateral postural (6 - 8 Hz) and kinetic tremor of the upper 
limbs but it may also affect the head, voice, legs, jaw, face, trunk and tongue(41 ;42) 
and is often mild(43). Those attending hospital clinics tend to have more severe and 
disabling disease. Some patients may have a rest component that usually occurs 
later in the disease course(44). Of 176 patients with a clinical diagnosis of ET, 10.2% 
had additional rest tremor(45). Postural instability and an ataxic gait are sometimes 
found(9) although are usually not predominant features. The cogwheel phenomenon 
is also a common confounding factor in ET. Tremor is sometimes asymmetrical and 
rarely can be unilateral. A positive family history occurs in around 50% of cases, and 
response to alcohol and beta-blockers is variable(46). In addition, subtle 
extrapyramidal signs (such as reduced facial expression, reduced arm swing, or 
stooped posture) are often found in the elderly. When these are present in patients 
with ET, they may reduce certainty of diagnosis. Post-mortem studies of ET have 
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failed to show abnormalities of the substantia nigra(47), although the localised 
presence of Lewy bodies within the locus ceruleus has been reported recently in a 
patient with longstanding typical essential tremor without parkinsonism(48), raising 
questions about the link between some patients with clinical essential tremor and 
restricted (non-nigral) forms of Lewy body disease. 
In a retrospective review of 201 consecutive patients attending our movement 
disorder clinic (Benamer and Grosset, unpublished observations), 68 (34%) had 
tremor only or a tremor-dominant syndrome. Of these, 31 had a diagnosis made by 
the referring clinician (mainly nonspecialist). Specialist clinical diagnosis concurred 
with the referral diagnosis in 14 of 21 cases referred as PO, but was changed from 
PO to ET in 6 cases, and from PO to uncertain in one case. Of 8 patients referred as 
a diagnosis of ET, 2 cases were confirmed in the clinic, but 5 cases were amended to 
PD. Of 2 patients referred with atypical tremor, the final diagnosis was 1 PO and 1 
ET. Additionally, 7% of initial diagnoses made by the movement disorder specialists 
changed during follow-up: 3 initial ET diagnoses changed to 2 PO and 1 possible 
cerebrovascular disease; 2 initial diagnoses of non-specific basal ganglia dysfunction 
were diagnosed with benign tremulous PO; 11 cases (16%) had tremor disorders of 
uncertain diagnosis throughout. These results emphasise that a shift between 
diagnoses occurs between tremor and degenerative parkinsonism, which is less than 
ideal not least from a patient and carer perspective. 
As ET is a relatively common disorder, some patients will develop both conditions, 
typically with initial features of ET and later the emergence of PO(49). The literature 
is inconclusive on the subject of whether there is a higher risk of PO developing in 
patients with ET, with some reports of no greater risk(50) and others of greater than 
expected risk(51 ;52). This uncertainty exists in part because clinical features of 
tremor sometimes fail to distinguish ET from PO cases. Prospective data is lacking 
on cases with initial normal functional imaging (in the ET phase) with subsequent 
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abnormal imaging (as PO develops), although there is some evidence for this 
process in rare families with a tendency to develop both ET and PD. The use of the 
term 'indeterminate tremor disorder'(53) is advocated by some to avoid the reversal 
of an initial incorrect diagnosis of ET or PO or even dystonic tremor. This definition 
applies to patients who satisfy the criteria of ET as set by the Tremor Investigation 
Group (TRIG) but exhibit other neurological signs of uncertain significance not 
sufficient to make the diagnosis of a recognisable disorder (for example, mild 
extrapyramidal features, such as hypomimia, decreased arm swing, or mild 
bradykinesia). 
1 c) Vascular parkinsonism 
Arteriosclerotic or vascular parkinsonism was initially described by Critchley(54) in. 
1929 but the concept has been controversial since, particularly because the initial 
description was not backed up by neuropathological correlations. A number of 
descriptions exist which include 'lower body parkinsonism' which describes gait 
ignition failure and parkinsonism in the legs and the term 'vascular pseudo-
parkinsonism' is perhaps more preferable in this context(55). Acute vascular 
parkinsonism, often secondary to lacunes in or near the ventrolateral nucleus of 
thalamus or globus pallid us externa tends to present with unilateral parkinsonism or 
shuffling gait with parkinsonism, whereas a more insidious type often related either to 
basal ganglia lacunes or diffuse small vessel disease more often presents bilaterally 
with shuffling gait, instability and falls, but later in the disease process these types 
are indistinguishable(56). An insidious onset with a latent period after acute stroke 
can also occur(56). Rest tremor occurs uncommonly but is not of the typical pill-
rolling type, and the upper limbs are commonly affected(56). There may be 
associated features of pyramidal tract signs or dementia or emotional lability. 
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The levodopa response is reported to be less although some patients will exhibit a 
positive response(57) associated with lesions in or close to the nigro-striatal pathway, 
and therefore this is not useful to differentiate between disorders on an individual 
patient basis. It is misdiagnosed as Parkinson's disease up until death, and a form 
which is similar to progressive supranuclear palsy has been described(58). 
Of 1500 consecutive patients assessed for movement disorders post-stroke, 5 
developed parkinsonism after 3 months and 1 developed it 10 months post-stroke 
which persisted in 5 of the 6 patients for over 3 years(59). Vascular parkinsonism 
comprises 3 - 6%(60) of subjects with parkinsonism. A mean illness duration of 3.1 
(range 1 to 9) years in a post-mortem series of 27 patients(61) and 10.9 (± 5.5) years 
in another series of 17 patients(56) was found in patients with a post-mortem 
diagnosis of vascular parkinsonism which is significantly different to the prognosis of 
Parkinson's disease. Co-existent vascular disease and Parkinson's disease worsens 
disease severity(62), and potentially could affect dopaminergic response although 
this has not been investigated. 
Diagnostic criteria were proposed in 2004(56) as follows; 
• a) Parkinsonism: bradykinesia and at least one of the following: rest tremor, 
muscular rigidity or postural instability (not due to primary visual, cerebellar, 
vestibular, proprioception dysfunction). 
• b) Cerebrovascular disease, defined by evidence of relevant cerebrovascular 
disease on brain imaging (CT or MRI) orthe presence of focal signs or 
symptoms that are consistent with stroke. 
• c) A relationship between the above 2 disorders. 
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In practice: 
• An acute or delayed onset with infarcts in or near areas that increase the 
basal ganglia motor output (globus pallid us externa or substantia nigra 
compacta) or decrease the thalamocortical drive directly (ventrolateral 
nucleus of the thalamus, large frontal lobe infarct). The parkinsonism at onset 
consists of a contralateral bradykinetic rigid syndrome or shuffling gait, within 
a year of stroke. 
• An insidious onset of parkinsonism with extensive subcortical white matter 
lesions, bilateral symptoms at onset, and the presence of early shuffling gait, 
or early cognitive dysfunction. 
1 d) Drug-induced parkinsonism 
Drug-induced parkinsonism is the second commonest form of parkinsonism after 
PD(63), involving dopamine antagonists used in psychiatry, and antiemetics. 
Typically it presents with less tremor, and more symmetrical and milder parkinsonian 
features, however it may be indistinguishable from PD(64) with asymmetrical 
parkinsonism and all the cardinal features(65-68). Depending on referral patterns, as 
many as 51 % of new cases may be associated with dopamine antagonist drugs(69). 
The incidence of extrapyramidal side effects with low dose neuroleptics is 32%(70). 
Drug induced parkinsonism (DIP) is easily recognised if there is a close relationship 
between onset of parkinsonism and use of dopamine depletors, but some patients 
can be taking drugs for years prior to onset of parkinsonism and recovery after drug 
can rarely take up to 18 months(71). "Unmasking" of pre-clinical PD by drug therapy 
has been confirmed at post mortem(72) and is reported in between 5 and 16% of 
drug-induced cases(15;73-76). 
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1e) Psychogenic movement disorders and psychogenic parkinsonism 
A 'psychogenic' movement disorder is a term which encompasses movement 
disorders which are somatoform or factitious or due to malingering and may exist 
alone or in combination with underlying organic disease. However, the distinction 
between 'non-organic' and 'organic' disorders is grey. A comparison of regional blood 
flow in patients with weakness due to hysteria versus controls and feigners showed 
that patients with hysteria exhibited a significant relative hypoactivity in the left 
prefrontal area regardless of laterality of symptom onset, an area which is specifically 
related to the internal 'choice' of action(77). Some feel that psychogenic movement 
disorders are under-recognised(78), but psychogenic parkinsonism is probably quite 
rare. Twenty-eight (3.3%) of 842 consecutive patients presenting with movement 
disorders to a specialty movement disorder clinic were diagnosed with psychogenic 
movement disorders(79) of which tremor (50%) was the most common followed by 
dystonia(18%), myoclonus (14%) and parkinsonism (7%) and 25% were felt to co-
exist with an underlying organic movement disorder. The outlook for patients with 
psychogenic movement disorders is not favourable with persistence in 90% after an 
average of 3.2 years follow-up and 95% of subjects have a diagnosis of mental 
illness(80). No examination finding or test specifically diagnoses psychogenic 
parkinsonism. The tremors of psychogenic parkinsonism and psychogenic tremor 
have the same characteristics including sudden onset, variable amplitude, variable 
type of tremor (complex) and evidence of remissions, distractibility, and entrainment 
of tremor frequency to another part of the body(81). Unlike true bradykinesia where 
there is a gradual reduction in amplitude and hesitation, the slowness found in 
psychogenic parkinsonism has a constant amplitude. Stiffness may be felt as a 
voluntary resistance to movement which differs from the cogwheeling or lead pipe 
rigidity in Parkinson's. The rigidity may decrease with synkinetic movements. The 
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arm may be held stiffly extended and adducted to the side, quite distinct to the 
reduced arm swing of PD(82). 
Diagnostic criteria for psychogenic movement disorders have been adopted(83). 
• Documented*: Persistent relief by psychotherapy, suggestion or placebo has 
been demonstrated, which may be helped by physiotherapy, or the patient 
was seen without the movement disorder when believing him- or herself 
unobserved. 
• Clinicallvestablished*: The movement disorder is incongruent with a classical 
movement disorder or there are inconsistencies in the examination, plus at 
least one of the following three: other psychogenic signs, multiple 
somatisations, or an obvious psychiatric disturbance. 
• Probable: The movement disorder is incongruent or inconsistent with typical 
movement disorder, or there are psychogenic signs or multiple somatisations. 
• Possible: Evidence of an emotional disturbance. 
*As only the first two categories provide a clinically useful degree of diagnostic 
certainty they have been combined to one category of "Clinicallv Definite". 
These criteria may help to reduce inappropriate diagnosis of psychogenic movement 
disorders, but many physicians remain unwilling to positively and formally identify 
patients with psychogenic disorder because of clinical uncertainty and historical 
awareness of misdiagnosis of organic ~isorders as psychogenic. 
1f) Dopa-responsive dystonia 
Dopa-responsive dystonia is an autosomal dominant condition with reduced 
penetrance causing nigrostriatal dopamine deficiency due to defects in dopamine 
synthesis without dopaminergic cell loss. Onset is usually in childhood with crural 
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dystonia, imbalance and slowness with marked diurnal variation, parkinsonism and 
sustained response to low dose levodopa without the long term side effects noted 
with Parkinson's disease(84). Rarely, patients may have few (e.g. only exercise 
induced cramps or dystonic posturing) or no symptoms during childhood and develop 
pure parkinsonism after the age of 40. 
19) Juvenile onset Parkinson's disease or Young onset Parkinson's disease 
Onset of parkinsonism under the age of 21 is described as juvenile parkinsonism and 
between 21 and 40 as young onset parkinsonism. Juvenile parkinsonism is very rare 
and most do not have Lewy bodies at post-mortem, whereas young onset 
Parkinson's patients do. Distinction needs to be made from other rare disorders 
causing parkinsonism such as DRD, Wilson's and the akinetic-rigid presentation of 
Huntington's disease(85). 
1 h) Parkinsonism and dementia 
Dementia with Lewy bodies (DLB) accounts for 11 % of community patients with 
dementia while Alzheimer's disease (AD) accounts for 31%(86); clinical features are 
at times similar. In DLB fluctuating dementia, visual hallucinations and 
hypersensitivity to neuroleptic medication coexist with parkinsonian features in 41 -
85%(87;88), but levodopa responsiveness is poorer than in PD and cognitive side 
effects greater(89). In AD progressive memory and higher cortical function decline, 
with neuropsychiatric features and myoclonus, which may be supplemented with 
parkinsonian signs in 5 -19% of cases(87;88). Parkinsonism in both conditions is 
milder than for PD, consisting mostly of rigidity and bradykinesia, while resting tremor 
is rare(90;91). 
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Clinical diagnostic accuracy for DLB improved from 50% in a clinicopathological 
study of 10 patients (in which 4 patients thought to have DLB had AD pathologically) 
to a sensitivity of 83% and specificity of 95% in part due to improved consensus 
criteria(92;93). In AD the positive predictive value of clinical diagnosis was 81 % 
against autopsy(94). However, some patients with pathologically confirmed DLB who 
had been misdiagnosed in life with AD did not show any typical features of DLB 
normally used to separate the two conditions(95). 
Extensive Lewy bodies are found in DLB and PO dementia (to distinguish the two, an 
arbitrary cut-off exists; if the onset of parkinsonism is more than 1 year prior to 
dementia then the diagnosis is PO dementia). Neurofibrillary tangles and senile 
plaques predominate in Alzheimer's. Included in the differential of these disorders is 
vascular dementia which can coexist and alter the clinical presentation. Corticobasal 
degeneration and Alzheimer's disease are sometimes mistaken as parkinsonism and 
apraxia can occur in both. 
2. Adjuncts to clinical diagnosis 
2a) Levodopa and apomorphine challenge tests 
The clinical response to acute dopamine challenge can be a useful adjunct to clinical 
assessment. A meta-analysis on levodopa and apomorphine challenge testing found 
that sensitivity for the diagnosis of established Parkinson's disease was 75 - 86% 
and specificity was 85 - 87% for acute challenge tests(96). The improvement seen in 
PO can also be found in some patients with multiple system atrophy and progressive 
supranuclear palsy. Eighteen of 22 patients misdiagnosed with Parkinson's disease 
studied in the Brain Bank post-mortem series(1) had a definite initial response to 
levodopa. Caution is recommended in early untreated Parkinson's disease where the 
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false negative rate may be as high as 40%(97). A retrospective analysis of initial 
levodopa response in pathologically confirmed Parkinson's disease found 'nil and 
poor' recorded in 6/96 (6%), although 'moderate', 'good' or 'excellent' were more 
typical (17%, 53% and 24% respectively)(19). 
2b) Olfactory testing 
In the earliest stages of Parkinson's disease there is olfactory disturbance albeit 
asymptomatic. Whilst it is not at all specific, various combinations of tests including 
olfactory function are being assessed to develop screening tools for populations at 
high risk of PO(98-1 00). 
2c) Genetic testing 
A number of genetic loci have been identified in familial PO but it is a sporadic 
disorder in the majority of patients and genetic testing is recommended only in very 
selected circumstances(1 01). 
2d) Structural brain imaging 
CT and MRI Brain Imaging 
Structural brain imaging with computed tomography (CT) or magnetic resonance 
imaging (MRI) is normal in Parkinson's disease and is used in the atypical case, to 
exclude parkinsonism caused by other pathologies such as hydrocephalus, 
cerebrovascular disease or tumours. Fairly specific abnormalities on conventional 
MRI in multiple system atrophy (MSA) in the putamen or infratentorial structures(1 02) 
have a low sensitivity in early disease when clinical diagnosis is less certain thereby 
limiting its usefulness as an aid to diagnosis in patients with inconclusive 
parkinsonism. In progressive supranuclear palsy (PSP), MR changes such as 
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atrophy of the superior cerebellar peduncle have low sensitivity(1 03). Advanced MR 
techniques such as diffusion weighted imaging may also be helpful to discriminate 
Parkinson's disease from atypical parkinsonism(104). 
Transcranial Ultrasound 
Transcranial ultrasound imaging of the midbrain though a bony window in the 
temporal area reveals increased acoustic signal within the substantia nigra (thought 
to reflect increased iron content) in Parkinson's disease but also in 9% of the normal 
population(1 05; 1 06). It is currently being assessed as a screening tool for 
Parkinson's disease together with tests such as olfactory function(98;99) which have 
similar high sensitivity but insufficiently high specificity for individual use as diagnostic 
tools. 
2e) Functional imaging 
Functional Brain Imaging of the dopaminergic system 
Indirect assessment of the presynaptic dopaminergic system involves radiolabelling 
fluoro-dopa (F-dopa), the vesicular monoamine oxidase transporter (V MAT) or the 
dopamine transporter (DAT) (Figure 1-1).The brain is imaged with SPECT (single 
photon emission computed tomography) or PET (positron emission tomography). 
F-dopa is a precursor of dopamine which is taken up by dopaminergic neurones and 
then dopa-decarboxylated by aromatic amino acid decarboxylase. Uptake of [18F]_ 
dopa imaged with PET provides an assessment of dopa decarboxylation. Storage of 
the dopamine in synaptic vesicles via the vesicular monoamine transporter 2 can be 
imaged with [11C] dihydrotetrabenazine PET. The dopamine transporter is a protein 
present only on the presynaptic dopaminergic neurone which actively re-uptakes 
dopamine and therefore regulates synaptic levels of dopamine. Single photon 
emission computerised tomography (SPECT) and positron emission tomography 
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(PET) are used to image ligands specific to the dopamine transporter, examples of 
which are, 
• for SPECT; [1231] FP-CIT, [1231] ~-CIT, C231] IPT, [99mTc] TROOAT 
• and for PET; [11C] CFT, [11C] RTI-32. 
Functional Brain Imaging of brain glucose metabolism with 
fluorodeoxyglucose (FDG) - PET 
One hundred and thirty five patients with parkinsonism were referred for C8F] FOG 
PET to assist in the differential diagnosis and were followed up for an average of 2.1 
years. Visual assessment of PET concurred with follow-up diagnosis in 88.4% for 
early PO, 97.2 % for late PO, 76% for !\liSA, 60% for PSP, 90.1% for CBO and 90.1% 
for normal volunteers. The concordance improved when an approach using statistical 
parametric mapping was used with a sensitivity of 100% and a specificity of 86% for 
a diagnosis of early PO as compared to normal controls(107). 
Functional imaging of the myocardial sympathetic nervous system. 
There is dysfunction of myocardial postganglionic sympathetic neurones in 
Parkinson's disease. Imaging of these neurones with lodine-123 
metaiodonenzylguanidine (MIBG) SPECT is abnormal in Parkinson's disease and 
may help differentiate PO from other disorders without postganglionic sympathetic 
dysfunction such as multiple system atrophy(108). The accuracy of this technique in 
the investigation of early disease is under investigation(1 09). 
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3. Functional Brain Imaging with dopamine transporter imaging 
3a) Comparison to other dopamine imaging techniques. 
OAT imaging enables in vivo demonstration of striatal dopamine activity (Figure 1-1). 
Results are in keeping with other observations (including autopsy studies) of the 
dopamine system(110-112). The OAT is a sodium chloride dependent protein on the 
presynaptic dopaminergic nerve terminal which controls dopamine levels by active 
reuptake of dopamine after its interaction with the post synaptic receptor(113). The 
OAT ligands for SPECT including [99mTc] TROOAT(114), [1231] I?>-CIT(115), C231] 
IPT(116), [1231] FP-CIT(117), have all shown significantly reduced striatal uptake in 
PO, including some rarer genetic forms(118; 119). Abnormal uptake progresses from 
putamen to caudate, and matches contralaterally the clinically more affected side. 
The time of scan acquisition varies: 20 to 24 hours for [1231] I?>-CIT; 3 to 4 hours for 
[ 1231] FP-CIT(120) and 4 hours for [99mTc] TROOAT(121). Image analysis uses 
quantitative region of interest (ROI) ratios and/ or qualitative visual grading. Striatal 
uptake is typically calculated in relation to a reference site with negligible OAT 
density (occipital or cerebellar cortex). Ligands differ, preventing direct comparison: 
the normal striatal ratio for [1231] FP-CIT was 2.3 in one study while for [1231] I?>-CIT it 
was 5.5(122); for [99mTc] TROOAT the normal striatal ratio was approximately 2(121). 
OAT imaging is reproducible: test/retest variability in health controls and PO was 7% 
for [1231] FP-CIT(123) and 13% in controls and 17% in PO for [1231] I?>-CIT(124). 
The effect of drugs on OAT expression needs consideration. Central nervous system 
stimulants (amphetamine, sympathomimetics including some nasal decongestants) 
are stopped for 4 weeks to prevent interaction. Theoretically an up-regulation of OAT 
expression secondary to dopamine excess should occur in patients treated with 
anti parkinson medication, but this has not been identified in animal or human drug 
studies(125). Antiparkinsonian therapy showed no significant effect on striatal [1231] I?>-
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CIT uptake with L-dopa or selegiline over 4 - 6 weeks(126) nor with pramipexole or 
levodopa over 10 weeks(127) and [1231] FP-CIT uptake did not change in patients 
taking levodopa monotherapy chronically after a washout period of 20 days(128). 
Pergolide was associated with a non-significant trend to increase striatal C23 1] r1-CIT 
uptake over 6 weeks(129). Effects of chronic antiparkinson therapy on OAT 
expression are less well studied, partly because of the interaction with changes from 
disease progression. 
Downregulation of OAT in early PO in an effort to maintain synaptic dopamine 
levels(130) does not negatively affect the sensitivity of the SPECT 
technique(131 ;132), even in very early presentation(133) and probably increases its 
sensitivity compared to C8F]-dopa PET. OAT abnormalities in patients with unilateral 
parkinsonism (Hoehn and Yahr 1) suggest significant preclinical dopaminergic nerve 
cellloss(134-136) and symptom threshold has been estimated from studies of 
patients with hemiparkinson's disease at between 42% and 64%(114;135-139) 
reduction of dopamine transporter uptake compared to controls. C23 1] r1-CIT identified 
asymptomatic cases amongst anosmic relatives of patients with PD(140). Striatal 
uptake correlates with duration and severity assessed by the Unified Parkinson 
Disease Rating Scale (UPDRS) motor scores and Hoehn and Yahr (H & Y) 
scores(134;141) and with age(142;143). The yearly rate of loss (or progression) of 
presynaptic dopaminergic neurones can be assessed by the reduction of the striatal 
uptake of radioligands and rates are similar whether assessed by dopamine 
transporter imaging radioligands (SPECT or PET) or [18F]-dopa PET and is in the 
region of 3 - 13% for PO and 0 - 2.5% in normals(115;127;144-156) and has become 
the focus for testing potentially neuroprotective drugs. 
OAT imaging is considered safe and radiation doses acceptable being roughly 
equivalent for a [1231] FP-CIT scan and a CT brain scan. A number of economic 
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assessments of the utility of OAT in patients with uncertain parkinsonism in different 
populations have been performed, with cost savings apparent at a prevalence of 
underlying true parkinsonism in the test population of 50% and below(157; 158). 
3b) Clinical application of dopamine transporter imaging 
In clinical practice OAT imaging assists mainly in patients in whom there is diagnostic 
doubt between true parkinsonism and other movement disorders. Testing may occur 
at baseline, or when clinically acceptable, after a period of monitoring which may 
include assessing therapy responses. 
Parkinsonism versus Essential Tremor 
The typical unilateral parkinsonian 4 - 6 Hz rest tremor is readily distinguished from 
the isolated postural symnietrical 6 - 12 Hz essential tremor. Additional parkinsonian 
features can secure a clinical diagnosis. However resting and postural tremor often 
coexist in both ET and PO(159). In PO, the action tremor may take two forms, a pure 
action tremor with no latent period which occurred in 61 % and a tremor that occurs 
after a latent period, known as re-emergent tremor and thought to represent a form of 
rest tremor, which occurred in 32% at a mean of 8 (SO 5) years after symptom onset 
and correlated to the severity of a rest tremor but not rigidity or 
bradykinesia(159).The tremorolytic effect of alcohol or propranolol is not specific to 
ET; the action tremor of PO responded in 46% of cases(46). When bradykinesia, 
rigidity or postural instability are mild or absent in early disease or have possible 
alternative causes, OAT imaging may prove invaluable in guiding accurate diagnosis 
and treatment plans. OAT studies are consistently normal in ET(160-162) in keeping 
with post mortem findings(47). Specificity of 100% (all of 27 cases) fulfilling clinical 
criteria for ET, and revision of diagnosis following normal C23 1] FP-CIT results, with a 
97% (154 out of 158) sensitivity for parkinsonism, provided the cornerstone for the 
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technique(161). Clinical diagnostic inaccuracy has been highlighted in further OAT 
imaging series: between 2%(127) and 14%(163) of patients labelled PO had normal 
[1231] ~-CIT, and 15% of early true parkinsonism diagnoses by movement disorder 
specialists and 30% of community neurologist diagnoses had normal [1231] ~-CIT 
SPECT, with increased congruence between imaging and clinical diagnoses at 6 
months(164). Longer follow up and ideally pathological confirmation is needed for a 
definitive resolution of rare persisting clinical image mismatches. Cases of possible 
ET (short-duration postural tremor, no other neurological features) consistently have 
normal OAT imaging(160;165), while mixed rest and postural tremor may be 
abnormal even in the absence of other significant parkinsonian features (2 of 6 
cases)(165). Abnormal dopamine transporter imaging was found in patients 
presenting with long duration asymmetrical isolated postural tremor initially 
diagnosed as ET and later fulfilling PO criteria(21). Inconclusive parkinsonian signs 
and normal C23 1] FP-CIT led to a change of diagnosis to essential tremor in 5 of 24 
cases(166). In conclusion, OAT imaging is helpful in tremor disorders particularly 
mixed postural and rest tremor with otherwise equivocal parkinsonian features. 
Idiopathic Parkinson's Disease versus Atypical Parkinsonism 
Clinical features of PO and atypical parkinsonian syndromes (PSP, MSA, CBO) 
overlap, but emerging "red flag" features often assist differentiation. A trend towards 
more symmetrical OAT loss in MSA and PSP compared to PO(167;168) and 
CBO(169) does not help individual case definition(168; 170). 
Combined OAT imaging and postsynaptic 02 receptor imaging may differentiate PO 
(OAT abnormal, 02 normal) from MSA and PSP (OAT and 02 both abnormal)(170). 
[1231] ~-CIT and [1231] IBF were separated by one week but a combined [99mTc] 
TROOAT-1 and [1231] IBZM or [1231] IBF SPECT suggests that image quality is 
adequate from simultaneous studies of OAT and 02(171). 02 imaging itself seems 
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to have poor sensitivity in early atypical parkinsonism, normal postsynaptic imaging 
in the early stages of an atypical disorder does not exclude MSA, PSP or CBO(172}. 
Group analysis of brain blood flow with [99m] Tc ECO SPECT in patients with MSA or 
PO may aid differentiation of groups, but is unlikely to help differentiation in 
individuals(173}. 
Parkinsonism versus Vascular Pseudo Parkinsonism (VP) 
Vascular parkinsonism (VP) in its classic form has predominantly lower body 
involvement with rigidity, short shuffling gait, less tremor, and poorer levodopa 
response than PO(174}, but there is a wide spectrum of clinical manifestation and VP 
and PO may co-exist(175}. [99mTc] TROOAT SPECT tested normal in 14 patients with 
VP and distinguished VP from PO(176}. A [1231] r.,-CIT study showed a 40% age 
corrected reduction in PO, greater left-right asymmetry, and lesser putamen-caudate 
ratios, all of which contrasted with near normal levels in VP(177}. Typical PO OAT 
abnormalities were found in 11 of 20 patients initially fulfilling vascular parkinsonism 
diagnostic criteria challenging the concept of vascular parkinsonism as a distinct 
entity and suggesting that cerebrovascular disease often co-exists with underlying 
PO(178}. OAT imaging may be abnormal in VP if there is focal basal ganglia 
infarction but the pattern of this "punched-out" SPECT deficit differs from the PO 
pattern(179}. 
Dementia with Lewy Bodies versus Alzheimer's Disease 
The post mortem evidence of dopamine dysfunction in OLB (72% reduction) and 
normal OAT in Alzheimer's disease(180} is largely confirmed in vivo: OAT binding 
was reduced in 27 patients with OLB and normal in 17 cases of Alzheimer'S disease, 
in caudate and anterior putamen. However, contralateral posterior putamen activity 
was 10% lower in AO than in controls, possibly due to age differences or inadvertent 
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inclusion of DLB patients misdiagnosed as AD(181). Post mortem diagnosis in 10 
cases correlated better with [1231] FP-CIT than with clinical diagnosis which showed a 
tendency to overdiagnose DLB. A sensitivity of 78% and a specificity of 94% with a 
positive predictive value of 90% was found when [1231] FP-CIT SPECT was used to 
separate AD and DLB groups fulfilling criteria, and of note 3 patients with DLB and no 
parkinsonism had abnormal DA T uptake although it was noted that further studies 
are required to assess accuracy of this technique in pre-motor DLB(182). 
Regional cerebral perfusion with [99m] Tc-HMPAO or [99m] Tc-ECD are abnormal in 
both AD and DLB but with different perfusion patterns. In DLB the temporal-parietal 
hypoperfusion typical of AD is present but in addition occipital "horseshoe" 
hypoperfusion was noted (6 of 7 patients). Combination perfusion and DAT studies 
may differentiate difficult cases(183). In conclusion DAT imaging differentiates AD 
for DLB, but it should be noted that DA T imaging may be abnormal in any dementia 
with nigrostriatal degeneration (e.g. fronto-temporal dementia with 
parkinsonism)(184). While post mortem is the gold standard, imaging studies are 
important with developments in dementia drug therapy. 
Parkinson's Disease versus Drug Induced Parkinsonism 
Parkinson's disease and DIP can present identically. Unmasking of subclinical PD by 
dopamine depletors occurs in a small but significant proportion of drug-induced 
cases(15;73-76) and antipsychotic medication withdrawal is not always desirable or 
achievable. As DA T density in the striatum is not altered by antipsychotic medication 
(because of the postsynaptic (D2) site of action of these drugs(185)) DAT imaging is 
potentially useful to differentiate those patients with pure drug-induced forms from 
those with underlying degenerative parkinsonism(65; 122; 186), especially in cases of 
unexpectedly severe or prolonged parkinsonism. 
26 
Dopa-Responsive Dystonia 
Dopa-responsive dystonia (DRD) and juvenile Parkinson's disease (JPD) are young-
onset familial disorders with parkinsonism and dystonia. Clinical distinction is 
important as prognosis and levodopa benefit differs. Imaging with C23 1] ~-CIT SPECT 
and [1231] FP-CIT shows normal dopamine transporter density in DRD and abnormal 
activity in JPD and PD(187-190). Imaging of the presynaptic striatal dopaminergic 
neurones with CBF] - dopa PET is normal even in the later onset cases with pure 
parkinsonism(191). Diagnostic difficulty such as in cases with negative family history 
can be assisted by DAT imaging. 
Psychogenic Tremor Disorders 
Clinically, psychogenic disorders are often complex with resting, postural and kinetic 
components and diagnosis is easier in the presence of variable tremor frequency, 
distractibility, or absence of other neurological signs(81). Diagnosis tends to be one 
of exclusion and is a protracted process, particularly when supporting features are 
not present. DAT imaging aids differentiation of psychogenic tremor from its main 
differential of PD(166;192;193) and has been used in combination with 
electrophysiological tremor recordings to improve diagnostic confidence(194). 
Other Uses for Dopamine Transporter Imaging 
Abnormal striatal DA T occurs in Wilson's disease to a level comparable with 
PD(195). [1231] TRODAT-1 striatal uptake was significantly reduced in 10 patients with 
spinocerebellar ataxia (SCA) 3 (Machado Joseph Disease)(196) and [123 1] FP-CIT is 
reduced in patients with SCA2 without parkinsonism(197) and in SCA17(198). 
Striatal [1231] IPT binding was moderately reduced in 18 patients with sporadic 
amyotrophic lateral sclerosis(199). [1231] FP-CIT is normal in patients with 
mitochondrial disorders such as chronic progressive external opthalmoplegia(200). In 
Gilles de la Tourette syndrome striatal C23 1] ~-CIT binding was 37% higher than 
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healthy controls(201). [1231] I!,-CIT binding is normal in idiopathic cervical 
dystonia(202). [1231] I!,-CIT and [1231]IPT is normal in patients with restless leg 
syndrome(203). Dopamine transporter imaging has been studied in small numbers 
in schizophrenia, alcohol dependence, cocaine, and methamphetamine dependence 
but these should be considered exploratory studies. 
Abnormal striatal uptake of [18F]-dopa PET in patients with neuroacanthocytosis, 
dentato-rubro-pallido-Iuysian atrophy and post-encephalitic parkinsonism has been 
described(204-207), although not reported with dopamine transporter imaging but 
one would expect similar changes. 
The impact of DA T imaging in patients with inconclusive parkinsonian 
syndromes. 
In inconclusive parkinsonism there are only 2 blinded prospective studies of the utility 
of dopamine transporter imaging, and both found the imaging diagnosis (of 
degenerative parkinsonism or not) to have a higher sensitivity and specificity than a 
specialist neurologist diagnosis at baseline when compared to a gold standard of 
blinded specialist diagnosis at 3(133) or 6 months(208;209). However, it has not yet 
been validated with longer term follow-up studies of patients with early tremor 
disorders to ensure congruence and to confirm correct clinical diagnoses. 
Application of OAT imaging in clinical case series guides application in routine 
practice as reported in the following 3 studies. In 33 patients with inconclusive 
parkinsonism followed for 2 - 4 years, 24 had no dopamine deficit, of whom 19 were 
diagnosed as non presynaptic parkinsonism, 3 had no confirmed diagnosis, one had 
MSA and one had PD. These 2 cases were described as clinically atypical(166). A 
therapy change was instigated in 72% of 118 patients after [1231] FP-CIT SPECT 
imaging results(21 0). A significant change in management or treatment was 
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undertaken in 28% of 90 patients studied retrospectively; scan results correlated well 
with clinical diagnoses during 14 months' observation(186). 
3c) Subjects with a clinical diagnosis of Parkinson's disease with scans 
without evidence of dopaminergic deficit (SWEDD's) 
Between 4 and 14% of patients diagnosed with early Parkinson's Disease and 
enrolled into trials of potential neuroprotective agents by movement disorder 
specialists have unexpectedly normal F-dopa or DAT imaging(163;211 ;212). These 
cases have been labelled as Subjects with scans Without Evidence of Dopaminergic 
Deficit (SWEDD's) and the interpretation oftheir significance is debated(213-215). 
There are three possibilities: 
1. Patients have been misdiagnosed as having Parkinson's disease and have a 
non-degenerative disorder such as essential tremor, vascular parkinsonism or 
drug-induced parkinsonism. 
2. Patients have Parkinson's disease but of a type not associated with 
nigrostriatal dysfunction. 
3. The sensitivity of the imaging in early Parkinson's disease is poor due to false 
negative results. 
Braaks' proposed neuropathological staging of Parkinson's disease suggests that 
nigrostriatal degeneration occurs at stage 3 after neuronal loss and Lewy body 
formation in the glossopharyngeal and olfactory nuclei(23). Theoretically, imaging 
prior to stage 3 should be normal. Stages 1 and 2 may manifest with anosmia or 
other non-motor features which are usually asymptomatic and in Braaks' study these 
subjects had escaped clinical recognition as PD. Because parkinsonism occurs after 
severe nigrostriatal depletion of 50 - 80%(24;25) and presynaptic dopaminergic 
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imaging detects 42 - 64% depletion in the asymptomatic putamen of patients with 
hemiParkinson's disease(114;135-139), imaging would be expected to be abnormal. 
Evidence of misdiagnosis comes from a number of sources. If the imaging technique 
had low sensitivity, but a progressive loss of uptake of 3 - 13% per annum(115; 144-
148;151 ;152;154;156) then normal images would become abnormal over time. In 
each of REAL PET(212), CALM-PD(211) and ELLDOPA(163) imaging was 
repeatedly normal up to 48 months. No progressive loss of radioligand uptake was 
seen on serial measurements over 48 months within the putamen in SWEDD's 
although this was seen in subjects with PD and abnormal scans(213). There is some 
evidence of an inverse relationship between the proportion of SWEDD's and the 
duration of disease, at least in the clinical trial population(163;211 ;212;215). Thus the 
accuracy of a PD diagnosis increases with longer follow-up. In ELLDOPA, SWEDD's 
did not have any response to levodopa even at high doses, which distinguished them 
from those with dopaminergic deficit(163). Further, the clinical validity of normal 
scans was supported by blinded video review of patients in ELLDOPA; 7 of 13 
SWEDD patients (54%) were thought unlikely to have PD by 3 or more out of 5 raters 
compared to 3 of 72 patients (4%) with abnormal scans(216). Finally, further 
evidence that movement disorder specialists do misdiagnose PD on entry into drug 
studies is found in follow-up of patients within the DATATOP study where 8.1 % had 
alternative diagnoses after 7.6 years although this included some cases of other 
degenerative parkinsonism(6). 
4. Summary of OAT imaging areas that require clarification 
Within the field of diagnostic dopamine transporter imaging there are therefore a 
number of questions that require clarification: 
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How do the findings of high accuracy of dopamine transporter imaging shown in 
those who fulfil criteria for Parkinson's disease and essential tremor(161; 162) 
translate to its use in routine clinical practice? 
How useful is OAT imaging to differentiate between degenerative parkinsonism and 
other mimics such as drug-induced parkinsonism or vascular parkinsonism and is it 
just as useful in each condition? 
What is the accuracy of OAT imaging in early, uncertain parkinsonian conditions? 
What is the meaning of normal OAT imaging in subjects with a PO diagnosis 
(SWEOO's)? 
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Figure 1-1 Schematic diagram of the pre and post synaptic dopaminergic 
neurone with reference to the specific components which can be radiolabelled 
and imaged with PET or SPECT 
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Chapter 2 : UK FP-CIT Case Collection Study 
Overview: Application of [1231] FP-CIT SPECT in 
clinical practice in the United Kingdom, experience in 
190 patients with uncertain parkinsonism 
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Introduction 
Several reports conclude that presynaptic dopaminergic imaging is useful in the 
differential diagnosis between degenerative and non-degenerative disorders 
featuring parkinsonism and! or tremor(133;161; 162;164;166; 186;21 0;217). Sensitivity 
ranges between 82 and 100% and specificity between 69 and 100%. However, there 
is an inherent bias in defining sensitivity and specificity when the results of the test 
under scrutiny have contributed to the working clinical diagnosis(166;186;210;217). 
With the exception of dementia conditions (and considering the differential diagnosis 
between Alzheimer's disease and Lewy body dementia), in which autopsy results 
corroborate dopaminergic imaging results(181), the veracity of the imaging results 
are primarily based on clinical diagnosis with follow-up for periods varying between 3 
months(133;164;186) and 4 years(166;217). The resulting lack of a 'truth' standard 
led one group to suggest that such testing was not yet appropriate in clinical 
care(218). On the other hand, [1231] FP-CIT SPECT scanning is licensed in Europe for 
the differential diagnosis of tremor and parkinsonism, and is in widespread use. An 
alternative approach to examine clinical utility is to study the effect of conducting 
dopamine transporter imaging on the prevailing clinical diagnosis. If the test is 
contributory to accurate diagnosis and management in clinically uncertain 
parkinsonism! tremor, changes in diagnosis and treatment plan post-scan should 
occur compared to pre-scan. Results might differ, and clinical utility vary, according 
to the clinical question raised and the potential differential diagnoses. Further, the 
presence of cardinal clinical features of degenerative parkinsonism should relate to 
abnormal [1231] FP-CIT scanning, more so when such features are definite than when 
they are possible(133). 
The present study therefore examined the clinical application of [1231] FP-CIT SPECT 
in patients with uncertain parkinsonism with 'paired' differential diagnoses (in each 
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case degenerative versus non-degenerative parkinsonism! tremor}. The predicted 
and actual scan result was compared, and the mismatch rate compared amongst the 
diagnostic pairings. This approach also allowed quantification of the proportion of 
[1231] FP-CIT SPECT scans in which a clear differentiation could be made between 
normal and abnormal, which is crucial in clinical care in the patient with clinical 
uncertainty(219} . 
Methods 
A multicentre prospective study in patients with uncertain parkinsonism where [1231] 
FP-CIT SPECT scanning was undertaken. Participating centres included Glasgow 
(x2), Aberdeen, Preston, London, Southampton, Northampton and Surrey. Patients 
with a definite or established clinical syndrome were excluded. Baseline clinical 
features and working diagnosis were registered centrally prior to imaging. 
Diagnostic pairings were between 
• degenerative parkinsonism (idiopathic Parkinson's disease, Dementia 
with Lewy Bodies, multiple system atrophy, progressive supranuclear 
palsy or corticobasal degeneration) 
and the following: 
• essential tremor (ET) or 'benign' tremor; 
• drug-induced parkinsonism (DIP); 
• vascular parkinsonism (VP); 
• dementia (Alzheimer's or vascular); 
• psychogenic parkinsonism and 
• dopa-responsive dystonia. 
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Any change in diagnosis after the referring clinician had reviewed the SPECT was 
recorded. Features were reported definite, possible or absent for each of rest and 
postural tremor, bradykinesia, rigidity and postural instability. Antiparkinson 
medication use, and the use of drugs with potential to cause drug-induced 
parkinsonism, previous and current, was recorded. 
Imaging procedures 
[123 1] FP-CIT SPECT was performed according to standardised methodology at each 
centre. Dopaminergic and other medication were continued except for agents that 
interfere with striatal [1231] FP-CIT uptake (central nervous system stimulants, anti-
anorexia and obesity treatments and sympathomimetics). 
Data processing 
[1231] FP-CIT SPECT scans were evaluated at each site in conjunction with clinical 
details. Visual grading was described as previously(161; 179): normalfor largely 
symmetrical uptake in putamen and caudate nuclei; abnormal grade 1 for 
asymmetrically reduced putamen activity; abnormal grade 2 for significant bilaterally 
reduced putamen uptake with activity confined to the caudate nuclei; and abnormal 
grade 3 for virtually absent uptake bilaterally affecting both putamen and caudate 
nuclei; abnorma/- focal as due to a structural lesion as detailed previously; and 
abnorma/- other if abnormal ligand uptake was in an atypical pattern (e.g. caudate 
loss greater than putamen, without a focal pattern). In calculating mismatches 
between clinical and imaging findings, an abnormal image (grade 1, 2 or 3) was 
defined as degenerative parkinsonism, while a normal or focal pattern was defined as 
non-degenerative, since a focal striatal vascular lesion does not always produce 
motor symptoms(220)). Abnormal (other) scans were considered separately. 
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Semiquantitative assessments for data sets acquired with the multidetector single 
slice system (SME 810, Neurofocus™) were performed in one centre using 
predetermined region of interest templates were from Ta/airach Daemon (online at 
http://ric.uthscsa.edu/projects/talairachdaemon.htmlaccessed July 14th 2006) and 
based on the Co-planar Stereotaxic Atlas of the Human Brain(221). Specific: non-
specific ratios were calculated from three adjacent axial slices through the regions of 
interest (ROI). The occipital region was used as reference for ROI analysis. The 
mean specific: non-specific ratios were calculated from the right and left-sided 
readings. Striatal readings were designated contralateral or ipsilateral according to 
the symptom onset side. A correction factor of 4% per decade was applied for each 
subject in keeping with published reports(137). 
Chapters relating to the UK Case Collection are arranged as follows: 
• This chapter (2) provides an overview of all cases and allows comparison of 
the application of [1231] FP-CIT SPECT within different subcategories and 
identification of patterns of diagnostic change across the different diagnostic 
pairings. 
• Chapters 3 & 4 relate to [1231] FP-CIT SPECT use in tremor disorders (mostly 
essential tremor) and drug induced parkinsonism respectively allowing 
appraisal of use and investigation of clinical features within these subgroups. 
Results 
One hundred and ninety patients (96 females: 94 males) aged 27-89 years (mean 
65, SO 13) underwent [1231] FP-CIT SPECT in 8 centres. Around two thirds of these 
patients were contributed from the Glasgow site. In all patients diagnosis was judged 
inconclusive by the referring specialist. [1231] FP-CIT SPECT was performed 1.3 
months after entry (95% CI 0.9 -1.7). Antiparkinson medication was used previously 
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but now discontinued in 7 (4%), currently in 37 (19%), never in 142 (75%) patients 
and not documented in 4 (2%). 
Of 190 patients entered, 101 patients (53%) had a pre-scan diagnosis of a non-
degenerative parkinsonian syndrome. SPECT was normal in 72 of those (71 %) and 
abnormal in 29 (29%), consisting of 22 with a degenerative parkinsonian pattern, 4 
with focal lesions and 3 'other'. The post-scan diagnosis was amended to 
degenerative parkinsonism in 20 of the 22 cases with abnormal SPECT in a 
parkinsonian distribution. 
Eighty nine (47%) had a pre-scan diagnosis of degenerative parkinsonism, of whom 
63 (70%) had an abnormal (degenerative parkinsonian) pattern (n = 60) or other 
pattern (n = 3). Twenty-six of this group of 89 (30%) had normal imaging; in 23 of 
these the post-scan diagnosis was amended (Table 2-1). SPECT results according to 
baseline diagnosis as degenerative or non-degenerative parkinsonism are shown in 
Figure 2-1. 
Overall the SPECT diagnosis and pre-scan clinical diagnosis disagreed in 49/190 
(26%), and agreed in 135 (71%) patients. In 6/190 (3%) the scan was abnormal 
(other). Excluding cases with abnormal (other) SPECT, congruence improved to 
179/182 (98.5%) between imaging and post-scan diagnosis (Table 2-2). Definite 
bradykinesia or definite rigidity were the strongest individual predictors of an 
abnormal SPECT. The strongest combined predictor of abnormal SPECT was 
definite bradykinesia, rigidity plus rest tremor (Table 2-3). 
Discussion 
This study reflects current application of [1231] FP-CIT SPECT in multiple United 
Kingdom centres. It is a unique prospective evaluation of the effect of [1231] FP-CIT 
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SPECT when considering diagnostic pairings in patients with tremor/parkinsonism. 
The study, and the proportion of potential drug-induced, psychogenic, or vascular 
causes, is one of the largest series involving functional diagnostic imaging. 
Concurrence rate in different diagnostic pairings 
Overall, the imaging result concurred with a similar proportion of cases when the 
clinical pre-scan diagnosis was non-degenerative parkinsonism (75%) as when it was 
degenerative parkinsonism (69%). 
However, the concurrence rate was only 44% for a pre-scan diagnosis of vascular 
parkinsonism, suggesting that degenerative parkinsonism is under diagnosed in 
patients with vascular risk factors. The clinician agreed with the abnormal scan in this 
group, changing the diagnosis to degenerative parkinsonism in 91 % post-scan. 
Vascular parkinsonism represents 3 - 5% of cases of parkinsonism(55) with some 
evidence of under(61) or over diagnosis(1). Co-existence of PO and cerebrovascular 
disease is 10 times more common than vascular parkinsonism alone(55), and 
cerebrovascular disease alters the phenotype of PO(62). Some imaging studies find 
normal or near-normal scans(176;177). A focal pattern matching structural 
change(179) was seen in 2% of our patients, not all of whom had a VP diagnosis, 
which is in keeping with asymptomatic striatal infarctions(220). Although almost half 
of the cases diagnosed as VP in two series had subnormal uptake(178;217) this was 
interpreted as coexisting degenerative parkinsonism, and in one series such patients 
were more likely to respond to levodopa(178). While uptake ratios may be reduced in 
VP, the pattern of abnormality is more symmetrical than in PO(177). The present 
results in the context of prior reports suggest that VP is likely when the scan is 
normal or shows a focal deficit, and is unlikely when graded putamenal then caudate 
loss is seen in the typical PO pattern. 
39 
Psychogenic parkinsonism is a rare but challenging diagnosis. In patients within this 
category, the scan agreed with a pre-scan psychogenic parkinsonism diagnosis in 
most (93%), much higher than the abnormal imaging rate (5 of 9 cases, 56%) in 
suspected psychogenic cases reported recently(194). However, in our series half of 
those patients where the pre-scan differential favoured degenerative rather than 
psychogenic parkinsonism had normal scans. An abnormal scan in this setting had a 
more specific effect on diagnosis (leading to a diagnosis of degenerative 
parkinsonism), but a normal scan led to a revised diagnosis of psychogenic PO in 
only half, others being labelled 'benign tremor disorder'. Adjunctive 
electrophysiological testing and prolonged clinical assessment has been 
suggested(194), but an alternative diagnosis may supervene. 
Forla differential between drug-induced parkinsonism and degenerative parkinsonism 
27% had abnormal imaging, which is lower than a rate of between 30%(222) and 
55%(65) reported in series of neuroleptic-induced parkinsonism. Differentiation is 
sometimes difficult as DIP can strongly mimic PO, with asymmetrical parkinsonism 
and cardinal features(65-68), improvement can be lengthy after drug cessation(71) 
and unmasking of presymptomatic PO occurs in between 5 and 16% of drug-induced 
cases(15;73-76). 
A change in diagnosis post-scan occurred in a quarter of cases (with increased 
congruence to imaging) but was more likely to occur in subgroups where 
parkinsonism was associated with dementia (43%) or dystonia (44%) than essential 
tremor (12%), vascular parkinsonism (29%), drug-induced parkinsonism (27%) or 
psychogenic parkinsonism (15%). 
Overall, 31 % of patients thought more likely to be degenerative parkinsonism before 
imaging had normal scans, although rates were higher (50 to 67%) within dementia, 
40 
psychogenic, and dystonic subcategories. The rate dropped to 2% post-scan, 
reflecting a strong influence of the scan result on clinical interpretation. Normal 
presynaptic dopaminergic imaging in patients diagnosed as early PO occurs in 
between 4 and 14% of cases entered in neuroprotective studies(127; 147;212}, which 
have been termed 'subjects with scans without evidence of dopaminergic deficit' 
(SWEOO's). Repeat normal imaging in these studies up to 48 months(127;147;212} 
found no evidence of progressive decline in uptake(213} which is counter to the 
anticipated reductions if PO was the correct diagnosis. Additionally patients with 
normal scans showed no therapeutic response even to high doses of levodopa(147} 
and blinded specialist video reviewers thought PO unlikely in 53% of SWEOO 
patients compared to only 4% with abnormal scans in ELLOOPA(216}. Although 
there is theoretical potential for PO to test normal with SPECT scan(214}, this 
occurrence is rare. 
Ninety-seven percent of images were readily categorised in this study, leaving only 6 
cases (3%) where the images did not fall into a recognisable pattern. Three (1.5%) 
had mildly reduced or borderline normal uptake whereas 3 (1.5%) had markedly 
reduced uptake in an atypical pattern. Atypical patterns may occur in atypical 
parkinsonian disorders where a symmetrical diffuse reduction of striatal uptake can 
occur, but this is not sufficiently discriminatory to differentiate PO from either 
MSNPSP or CBO(167;168;223;224}. Two of 3 cases with borderline normal SPECT 
results were within the possible drug-induced category (1 neuroleptic, and 1 
valproate). These cases may be examples of pre-symptomatic degenerative 
parkinsonism being unmasked by dopamine depleting drugs(219}. SPECT was 
borderline in a similarly small proportion of cases of clinically uncertain parkinsonism 
in two other studies: between 1 %(21 O) and 6%(186}. In such cases, visual 
assessment, semiquantitative data, and age matching along with caudate/ putamen 
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asymmetry indices and with structural imaging may be helpful together with clinical 
monitoring. 
It is notable that each of the cardinal features of PO is more definite when the scan is 
abnormal. This was reported previously(133), but in the current study the proportion 
of patients with definite signs and normal scans was higher, such that 43% of cases 
who fulfilled Brain Bank criteria part 1 had normal imaging. As expected, postural 
tremor had a stronger association with normal scans than other clinical features. 
In inconclusive parkinsonism there are only 2 blinded prospective studies of the utility 
of dopamine transporter imaging, and both found the imaging diagnosis (of 
degenerative parkinsonism or not) to have a higher sensitivity and specificity than a 
specialist neurologist diagnosis at baseline when compared to a gold standard of 
blinded specialist diagnosis at 3(133) or 6 -12 months(209;216). Our study does not 
define the accuracy of dopamine transporter imaging but provides measures of its 
clinical utility in routine practice and identifies which categories of patients appear to 
have higher rates of misdiagnosis of parkinsonian conditions. 
Conclusion 
This large multicentre study found that in patients with diagnostic uncertainty 
between pairings of degenerative and non-degenerative parkinsonism, 
[123 1] FP-CIT SPECT categorised 97% of scans as either normal or abnormal 
(degenerative, or focal). In one quarter of patients, the baseline clinical diagnosis was 
inconsistent with the SPECT result, leading invariably to a revised clinical diagnosis. 
In the 3% of patients with other abnormal/borderline C23 1] FP-CIT SPECT results, 
diagnosis remains less certain. 
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Table 2-1 Pre and post-scan most likely diagnoses and [1231] FP-CIT SPECT 
result in 190 patients with clinically uncertain parkinsonism 
Diagnosis pre-scan C23 1] FP-CIT SPECT result 
(231[ FP-C/r SPECr expected to be normal (or focal) (101) 
Non-degenerative parkinsonism Normal (72) 
(101 ) 
Abnormal grade 1,2 or 3 (22) 
Abnormal (focal) (4) 
Abnormal (other) (3) 
Diagnosis post-scan 
Non-degenerative parkinsonism (70) 
Not yet diagnosed (1) 
Normal (1) 
Degenerative parkinsonism (21) 
Non-degenerative parkinsonism (1) 
Non-degenerative parkinsonism (4) 
Non-degenerative parkinsonism (1) 
Uncertain (2) 
[1231[ FP-C/r SPECr expected to be abnormal (degenerative parkinsonism pattern) (89) 
Degenerative parkinsonism (89) Normal (26) Non-degenerative parkinsonism (23) 
Degenerative parkinsonism (2) 
Normal (1) 
Abnormal grade 1,2 or 3 (60) Degenerative parkinsonism (60) 
Abnormal (other) (3) Degenerative parkinsonism (1) 
Non-degenerative parkinsonism (1) 
Uncertain (1) 
For definitions of scan grades see text 
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Figure 2-1 Visual assessment of [1231] FP-CIT SPECT according to baseline 
diagnosis in 190 patients with uncertain parkinsonism 
a. (upper panel) patients with an initial diagnosis of degenerative parkinsonism 
b. (lower panel) patients with an initial diagnosis of non-degenerative parkinsonism 
_ Abnormal (parkinsonian pattern) 
c:=:J Normal (normal or focal pattern) 
1_4001 Uncertain 
100 
-~ ~ 75 
1/1 
-
(.J 50 Q) 
'E 
::::I 
(J) 25 
0 
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Table 2-2 Congruence between [1231] FP-CIT SPECT result and clinical 
diagnosis after knowledge of SPECT result in 190 patients 
SPECT result SPECT & post- SPECT & post- Uncertain Total 
scan diagnosis scan diagnosis 
match mismatch 
Patients with easily" caterzorised ~"2"311 FP-CIT SPECT 
Normal 94 2 2* 98 
Abnormal 81 1 0 82 
( degenerative 
parkinsonism) 
Abnormal 4 0 0 4 
(focal) 
Total 179/184 (97%) 3/184 (2%) 2/184 (1 %) 184 
Patients with l"2"311 FP-CIT SPECT in 'other' distribution 
Abnormal 6** 6 
(other) 
Total 190 
* = diagnosis not yet known 
** = cases in this group not assigned match or mismatch as scan interpretation is 
uncertain 
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Table 2-3 Relationship of individual and combination parkinsonian signs to 
abnormal [1231] FP-CIT SPECT (in a parkinsonian distribution) in 190 patients 
Bradykinesia 
Rigidity 
Postural Instability 
Rest tremor 
Postural tremor 
Bradykinesia and Rigidity and Rest tremor 
Brain Bank criteria (part 1) 
Bradykinesia and Rigidity andlor rest tremor 
Definite Possible 
Abnormal scans I total cases with feature (%) 
56197 (58%) 15/47 (32%) 
56/93 (60%) 
27/46 (59%) 
49/105 (47%) 
26/91 (29%) 
14/28 (50%) 
4/10 (40%) 
3/7 (43%) 
3/7 (43%) 
29/47 (62%) All scored definite 
53/93 (57%) All scored definite 
52/97 (54%) Each scored either definite or possible 
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Chapter 3 : A prospective assessment of the 
usefulness of [1231] FP-CIT SPECT in uncertain tremor 
disorders in clinical practice. A subgroup of the UK 
FP-CIT Case Collection 
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Introduction 
The commonest disorders presenting to neurology or movement disorders clinics 
with a tremor are essential tremor and idiopathic Parkinson's disease. These are 
usually easily differentiated. In cases where the clinical diagnosis is not so clear cut, 
functional imaging of the presynaptic dopaminergic neurones can be helpful. This 
chapter focuses on cases entered into the United Kingdom FP-CIT Case Collection 
Study where the pre-scan categorisation was into the diagnostic pairing of PO versus 
essential tremor. The usefulness of dopamine transporter imaging in movement 
disorder clinics has been characterised with [1231] FP-CIT SPECT in prospective 
studies of early stage tremor patients(133), clinically uncertain 
parkinsonism(166;210) and both retrospectively and prospectively with [123 1] r.,-CIT 
SPECT(164; 186). However, prior studies have been criticised as being mostly single 
centre in patients with established clinical diagnosis(225). The aim of this prospective 
study was to identify what proportion of patients with clinically uncertain tremor 
disorders have abnormal C23 1] FP-CIT SPECTimaging, and relate that to the pre-
scan working diagnosis, and to the documented clinical features. It relates to the 
routine practice of specialists in movement disorders and neurology in the United 
Kingdom. 
Methods 
Methods are detailed within Chapter 2 (Overview of the UK [1231] FP-CIT Case 
Collection Study) 
Results 
Fifty patients (30 females: 20 males) of median age 66 (interquartile range [IQ] 58 -
74) years underwent [123 1] FP-CIT SPECT in 6 centres. In all cases, diagnosis was 
judged inconclusive by the referring movement disorder specialist (n = 47) or general 
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neurologist (n = 3). Patients' data was transmitted centrally prior to imaging in all but 
6 cases (88%). [1231] FP-CIT SPECT was performed 33 days after entry (95% 
confidence interval [CI] 23 - 90). 
SPEeT result and post-scan diagnoses according to pre-scan diagnosis 
Of 50 patients entered, 27 (54%) had a provisional, pre-scan diagnosis of idiopathic 
Parkinson's disease, of whom 20 of 27 (74%) had an abnormal scan in keeping with 
the clinical diagnosis. Seven of 27 (26%) had normal imaging; in 6 of these the post-
scan diagnosis was amended to non-PO; in one the diagnosis of PO remained 
despite normal imaging (Table 3-1). 
Twenty-three patients (46%) had a pre-scan diagnosis of essential tremor and 
SPECT was normal in 19 (83%) supporting the clinical diagnosis. In 3 patients (13%) 
it was abnormal indicating presynaptic dopaminergic degeneration and in all 3 the 
post-scan diagnosis was PD. In the 1 remaining case (4%) there was a focal deficit 
related to previous cerebral haemorrhage and the post-scan diagnosis remained 
essential tremor. Visual grading of all SPECT images is summarised in Table 3-2. 
An overall comparison of expected and actual SPECT results found unexpected 
SPECT findings (mismatches) in 10 of 50 (20%), and 9 of these 10 mismatches 
(90%) changed diagnostic groupings accordingly (therefore, the pre to post-scan 
diagnostic mismatch rate was 18%, Figure 3-1). Table 3-3 charts the clinical 
characteristics of these mismatch cases. 
Tremor characteristics 
Table 3-4 shows [1231] FP-CIT SPECT results and post-scan diagnosis according to 
clinicians' scoring of tremor characteristics with descending order of tremor type 
(categorised according to the presence of rest and postural components). Two of 10 
patients (20%) with definite rest tremor without a postural component had normal 
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scans with a post-scan diagnosis of a benign tremor disorder. Two of 8 patients 
(25%) with definite postural tremor without a rest component had abnormal imaging 
and a post-scan diagnosis of PD. Tremor asymmetry and post-scan diagnosis are 
detailed in Table 3-5 and detailed information regarding tremor duration, predominant 
type, distribution and asymmetry and motor sub-score of Unified Parkinson's Disease 
Rating Scale (UPDRS) was available in 25 cases (Table 3-6). 
Relationship of clinical certainty in cardinal features to abnormal [1231] FP-CIT 
SPECT 
Twelve of 20 cases (60%) with definite bradykinesia had an abnormal [1231] FP-CIT 
and 6 of 20 cases (30%) with possible bradykinesia had abnormal scans. Twelve of 
20 cases (71%) with definite rigidity had abnormal scans which was the strongest 
individual cardinal feature of parkinsonism which predicted an abnormal scan. 
Definite postural tremor was scored in 12 of 35 cases (34%) with abnormal imaging. 
The strongest combined clinical profile in those with abnormal scans was definite 
bradykinesia, rigidity and rest tremor. Individual and combinations of clinical features 
are reported in relation to abnormal [1231] FP-CIT SPECT in Table 3-7. 
Diagnostic confidence 
The average diagnostic confidence in those cases where the scan concurred with the 
clinician's initial diagnosis of PO was 70% (95% CI 66 - 74) and post-scan it was 94% 
(95% CI 93 - 95). For an ET diagnosis pre-scan confidence was 65% (95% CI 60 -
70) and post-scan 87% (95% CI 85 - 89). For all cases where pre and post scan 
diagnoses matched, the clinician's confidence increased from 68% pre to 90% post-
scan. 
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Influence of [1231] FP-CIT SPECT or clinical progression on management plan 
The management plan changed post-scan in 30/50 (60%). In 29/50 (58%) this was 
attributable to the scan (plus other reasons in 4) and 1/50 (2%) to clinical progression 
only. 
Discussion 
According to the pre-scan diagnosis, the predicted and actual [123 1] FP-CIT SPECT 
result differed in one fifth of cases and the post-scan diagnosis was changed by the 
referring clinician in almost all of the mismatch cases in line with the scan result. In 
these mismatches the management plan changed in nearly all patients and in most 
this related to the scan result. These results are a measure of the strong influence of 
the [1231] FP-CIT SPECT on the clinicians' diagnosis and management of patients 
with atypical tremor disorders. 
In a large blinded series of 158 patients who fulfilled diagnostic criteria, the sensitivity 
of [1231] FP-CIT imaging for the clinical diagnosis of parkinsonism was 97% and 
specificity for ET was 100%(161) whereas a similar study with 96 patients and [1231] 
I1-CIT SPECT, found a sensitivity of 98% and specificity of 83%(162) for a diagnosis 
of degenerative parkinsonism. Diagnostic error is present even when patients fulfil 
clinical criteria. The 'last visit pre-mortem' diagnosis is incorrect for between 10(32) 
and 25% for PD(19). Since C23 1] FP-CIT SPECT cannot reliably distinguish amongst 
degenerative parkinsonism, not all of the misdiagnoses can be corrected with this 
test. In the original Brain Bank study 12 of 25 cases (52%) where PD was 
misdiagnosed (or 12% of the whole population with an PD diagnosis) would be 
expected to show normal dopamine transporter or F-dopa imaging (these 12 cases 
were made up of the following: Alzheimer's or Alzheimer-type pathology n = 6; 
vascular n = 3; nigral atrophy n = 2 and normal n = 1). Higher mismatch rates earlier 
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in the clinical course and in patients with greater clinical uncertainty would be 
expected. 
Concurrence of clinical diagnosis and [1231] FP-CIT SPECT result 
The baseline mismatch rate between preliminary diagnosis and SPECT result was 
one fifth which is similar to that reported in studies of uncertain parkinsonism of 
between 14% and 34%(133;164;186}. Comparisons between studies can be made, 
but are somewhat limited because not all described the baseline diagnosis, blinding 
of the studies varied and some were retrospective assessments. These studies are 
reviewed below. 
A mismatch between referral diagnosis and [1231] f1-CIT SPECT was found in a 
retrospective study in 23% of 90 patients who had a primary, tentative diagnosis of 
parkinsonism. At a mean of 14 months later, a high proportion of clinical diagnoses 
concurred with baseline imaging with an imaging sensitivity of 97% and a specificity 
of 83%(186}. Similar sensitivity (96%) was found in our study but we found higher 
specificity of imaging for the post-scan diagnosis of degenerative parkinsonism 
(100%). In a study of 33 patients with inconclusive parkinsonian syndromes and [1231] 
FP-CIT SPECT, clinical diagnosis after 2 - 4 years concurred with the scan result in 
31 cases(166} and gave a sensitivity of 82% and a specificity of 100%. Our study 
was not a follow-up study; rather it assessed the immediate influence of imaging on 
diagnosis and management. The calculation of sensitivities and specificities for an 
imaging result according to a diagnostic gold standard which is influenced by the 
imaging result itself is circular. Clearly post-mortem is the true gold-standard but this 
is difficult to achieve in tremor disorders especially when including benign cases and 
there are no reports of such patients available. Nevertheless, our standard provides 
the radiologist! nuclear medicine physician with an indication of the influence of 
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dopamine transporter imaging on diagnostic thinking by the movement disorder 
physician! neurologist. 
Evidence that blinded clinical diagnosis concurs with baseline scan results after 
follow-up is found in 2 studies of early and uncertain parkinsonian disorders. In the 
first study, mismatch between baseline blinded clinical diagnosis and baseline 
imaging occurred in 11 of 62 patients (18%) which decreased to 10% at 3 months 
with amendment of blinded clinical diagnoses(133). Three year follow-up of these 
patients, within an extended multicentre study, is reported in Chapter 6. In the 
second study, mismatch between baseline [1231] I1-CIT SPECT and referral diagnosis 
was between 14% and 34% (lower for movement disorder experts versus community 
neurologists) which reduced at blinded clinical review at 3 to 6 months to 9% of 
patients. No mismatches were identified at 12 month blinded review(226), although 
numbers completing the 12 month follow-up were low. 
Change in management after knowledge of [1231] FP-CIT SPECT result 
The largest study to assess [1231] FP-CIT SPECT in uncertain parkinsonian 
disorders(21 0) found an impact in most of 118 patients (increased confidence or 
change in diagnosis) with a change in baseline diagnosis after imaging in 53!109 
(49%) and change in clinical management in 72%, which included changes in current 
and planned pharmacological management. Just over half of the patients in our 
tremor study had a change in management which was attributed by the local clinician 
to the imaging result. 
Post-scan diagnoses 
The heterogeneity of the post-scan diagnosis of those cases with normal [1231] FP-CIT 
SPECT is interesting. Clearly not all cases have a straightforward diagnosis of 
essential tremor but have contributions from other conditions such as vascular 
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disease or tremorogenic medications and represents the complex mix of conditions 
that are seen in everyday practice rather than cases that strictly fulfil criteria and are 
thereby invited to clinical trial entry or observational clinical research(53). This study 
therefore confirms the utility of dopamine transporter imaging in this mixed patient 
population. 
One patient kept a diagnosis of Parkinson's disease despite the unexpectedly normal 
C23 1] FP-CIT SPECT. This has been previously observed in numerous studies 
assessing usefulness of functional dopaminergic imaging in early or uncertain 
parkinsonian disorders(133; 166; 186). Booij found that after clinical follow-up, 2 of 24 
(8%) patients had a diagnosis of true parkinsonian syndrome despite no evidence of 
nigrostriatal degeneration on imaging(166). Baseline imaging of patients with a 
clinical diagnosis of early PO into CALM-PO(127), REAL-PET(212) and 
ELLOOPA(147) therapy trials showed normal scans in 4, 11 and 14% respectively. 
This issue of these so called 'SWEOO's' (subjects without evidence of dopaminergic 
deficit) is controversial. While some believe that clinical diagnosis is correct and 
consider imaging techniques in de novo patients to be poorly sensitive(227), others 
consider these patients to have been misdiagnosed. 
Clinical features of tremor disorders 
Our study concurs with other studies that find an atypical presentation of PO in some 
cases, such as patients with postural tremor (and no rest component)(21 ;228), 
predominant postural tremor (with rest component) and symmetrical tremor, and of 
asymmetrical rest tremor in ET(229). We did not attempt to describe whether 
postural tremors when present were due to a re-emergent rest tremor(230), nor 
whether the rest component was classic pill-rolling type associated with PO or of 
flexion! extension type often associated with essential tremor, although this is likely to 
have been clinically useful. The presence of 3 cardinal features scored as definite 
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(rest tremor, rigidity and bradykinesia) predicted an abnormal [1231] FP-CIT SPECT in 
only three-quarters of cases in the current series which is lower that that found in a 
2-centre prospective study of early tremor disorders (100%)(133). Also, less than two 
thirds of patients fulfilling Brain Bank criteria part 1 in the current series had abnormal 
imaging which emphasises that the presence of cardinal features is not specific to 
the presence of an abnormal scan. 
Conclusion 
The clinical misdiagnosis rate in early tremor disorders with parkinsonism in routine 
practice is high and C231] FP-CIT SPECT influences diagnosis, management and 
clinicians confidence in the majority of cases. Although this was an observational 
study and clinicians were not blind to the SPECT result, the improved congruence 
between diagnosis and imaging was in keeping with that found in blinded studies and 
reaffirms the utility of dopamine transporter imaging in. uncertain tremor! parkinsonian 
disorders in routine clinical practice. 
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Table 3-1 Comparison of pre and post-scan diagnoses according to [1231] FP-
CIT SPECT of 50 patients with uncertain tremor disorders 
Pre-scan diagnosis 
Parkinson's disease 
(scan expected to be 
abnormal) 
(n = 27) 
Essential tremor 
(scan expected to be 
normal) 
(n = 23) 
[ 1231] FP-CIT SPECT 
Abnormal - parkinsonian 
distribution 
(n = 19) 
Abnormal - other* 
(n = 1) 
Normal 
(n = 7) 
Abnormal - parkinsonian 
distribution 
(n = 3) 
Abnormal - focal 
(n = 1) 
Normal 
(n = 19) 
Post-scan diagnosis 
17 PD 
1 atypical parkinsonian 
disorder (loss of D2 
receptors detected by C23 1] 
18ZM SPECT and PSP 
diagnosis) 
1 atypical parkinsonian 
disorder 
1 PD 
4 ET 
1 atypical ET or vascular 
1 ET ± valproate tremor 
2 PD 
1 PD + ET 
1 ET 
16 ET (2 with contributions 
from lithium, valproate, 
dystonic or vascular 
component) 
1 orthostatic tremor 
1 drug induced 
(trifluoperazine) ± vascular 
1 vascular ± alcohol excess 
ET = essential tremor, PD = Parkinson's disease, *SPECT has reduced uptake in a 
symmetrical pattern and is unlike that seen typical in PD. 
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Table 3-2 Visual grade of [1231] FP-CIT SPECT according to pre-scan diagnosis 
in 50 patients with uncertain tremor disorders 
Pre-scan Normal Abnormal SPECT* 
diagnosis SPECT Grade 1 Grade 2 Grade 3 Focal Other 
PO 7 6 11 2 0 1 
(n = 27) atypical ** 
ET 19 2 1 0 1 0 
(n = 23) 
*For visual grade definition see introduction 
**There was no preferential loss of [1231] FP-CIT from the putamen. 
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Figure 3-1 Pre-scan to post-scan diagnostic mismatch rate in 50 patients with 
uncertain tremor disorders 
SPEer ex~ected to be 
~ 
Pre-scan diagnosis Abnormal Normal 
PO ET 
n= 27 n = 23 
~ ~ ~ ~ 
Post-scan diagnosis PO 21** ET* 6 PO 3 ET* 20 
(scan result) (20 abnormal (6 normal) (3 abnormal) (18 normal, 
1 normal) 1 focal) 
(78%) (22%) (13%) (87%) 
~ 
Mismatch rate 
18% 
*Includes vascular, dystonic, atypical, orthostatic tremors where [1231] FP-CIT SPECT 
expected to be normal. **One case here had a normal scan but clinician scored it still 
as PD. 
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Table 3-3 Clinical characteristics of 10 'mismatch' tremor cases 
No Symptom and Signs Pre-scan Post-scan Change in Management plan 
(sex, diagnostic diagnosis management 
age) confidence and plan? Due to 
confidence scan? 
Pre-scan diagnosis PD; 118 Tremor right hand, worse carrying pans, PD70% ET or DIP Yes Anti tremor therapy and/or 
normal e231] FP-CIT SPECT; (F, micrographia. Definite rest and postural 80% Due to scan change of anti epileptic 
post-scan diagnosis non-PD 66) tremor, predominantly postural in both arms result medication under consideration 
(n = 6) with definite rigidity and bradykinesia. On 
valproate 
4 Definite rest and postural tremor, possible PD65% ET 70% No Anti tremor therapy under 
(F, bradykinesia consideration 
65) 
13 Definite rest tremor, possible postural tremor, PD 50% ET95% Yes Anti tremor therapy to be started 
(M, bradykinesia and postural instability Due to scan 
51) result 
17 Definite rest tremor and rigidity PD60% Atypical ET Yes Anti tremor therapy under 
(F, or vascular Due to scan consideration 
44) 60% result 
20 Definite rest and postural tremor and possible PD70% ET70% Yes Anti tremor therapy under 
(F, bradykinesia Due to scan consideration 
81) result 
24 Definite rest and postural tremor and possible PD60% ET85% Yes Plan to reduce or stop 
(M, bradykinesia. On antiparkinson medications Due to scan antiparkinson medication and 
58) prior to imaging result thalamic deep brain stimulation 
under consideration 
Pre-scan diagnosis PD; 6 Definite bradykinesia and rigidity with possible PD90% PD 90% No Antiparkinson therapy to start 
normal [1231] FP-CITSPECT; (F, rest and postural tremor 
post-scan diagnosis PO (n = 1) 52) 
Pre-scan diaI;lnosis ET; 126 Long history of tremor diagnosed as essential ET5% PD 100% Yes Reduce to stop anti tremor 
abnormal [12 I] FP-CIT SPECT; (F, tremor with recent progression, falls & and ET Due to scan therapy and start antiparkinson 
post-scan diagnosis 66) deteriorating mobility. Symmetrical and result and therapy 
degenerative parkinsonism definite rest and postural tremor, bradykinesia, because of 
(n = 3) rigidity and postural instability specialist review 
1 Definite rest tremor, possible bradykinesia ET25% PD95% Yes Start antiparkinson therapy 
(F, Due to scan 
67) result 
12 Definite rest and postural tremor, possible ET50% PD 70% Yes Antiparkinson therapy under 
(F, bradykinesia and rigidity Due to scan consideration 
55) result 
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Table 3-4 Stratification of [1231] FP-CIT SPECT result and post-scan diagnosis 
according to tremor type in 50 cases 
Patient No Tremor t:lpe SPECT* Post-scan diagnosis 
(sex, age) Rest Postural 
103{M,61} y 1 PO 
124 {F, 80} Y 2 PSP 
110 {M, 82} Y 2 PO 
01 {F, 67} Y 1 PO 
02 {M, 67} Y 1 PO 
14 {M,71} Y 2 PO 
15 {M, 70} Y 2 PO 
23 {F, 70} Y 2 PO 
08 {F, 82} Y Normal ET 
17 {F, 44} Y Normal At~~ical ET & vascular tremor 
111 {M, 67} Possibl~ 2 PO 
104 {M, 59} Y Possibl~ 3 PO 
106 {F,45} Y Y 2 PO 
109 {F, 77} Y Y 2 PO 
119{F,75} Y Y Other A~~ical PO** 
126 {F, 66} Y Y 2 . PO + ET 
03 {M, 57} Y Y 1 PO 
12 {F, 55} Y Y 1 PO 
16 {F, 44} Y Y 1 PO 
19 {M, 63} Y Y 1 PO 
21 {M, 66} Y Y 3 PO 
25 (M, 80} Y Y 1 PO 
26 (M, 64} Y Y 2 PO 
102 (F, 74} Y Y Normal ET 
105 {F, 72} Y Y Normal ET 
107 (M, 65} Y Y Normal ET 
108 (F, 55} Y Y Normal ET 
112 {F, 75} Y Y Normal ET+VP 
117 (F, 62} Y Y Normal ET 
118 (F, 66} Y Y Normal ET OR DIP 
120 (F, 56} Y Y Normal VP ± DIP 
09 (F, 59} Y Y Normal ET 
122 {F, 75} Y Y Normal ET 
123 (M, 64} Y Y Normal VP or alcohol related tremor 
125 {F, 76} Y Y Normal ET 
04 (F, 65} Y Y Normal ET 
11 {F, 74} Y Y Normal ET or Lithium 
13(M,51} y Y Normal ET 
20 (F, 81} Y Y Normal ET 
24 (M, 58} Y Y Normal ET 
22 (F, 81} Y Y FOCAL ET 
115{M,47} Y 2 PO 
116{F,75} Y 2 PO 
113 {M, 35} Y Normal ET 
114 {M, 63} Y Normal ET 
121 (F,48} Y Normal ET OR DIP 
07 {F, 70} Y Normal ET 
10 (F, 74} Y Normal ET & orthostatic 
18 (M, 55} Y Normal O~stonic Tremor 
06 {F, 52} Possibl~ Possibl~ Normal PO 
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Y = yes, BLANK = NO, ET = essential tremor, PD = Parkinson's disease, DIP = drug 
induced parkinsonism, VP = vascular parkinsonism, Atypical PD = atypical 
degenerative parkinsonian disorder, PSP = progressive supranuclear palsy. 
*C 23 1] FP-CIT SPECT is reported as normal or graded 1, 2 or 3 (see text) or other. 
Other = striatal uptake is markedly reduced but does not have the preferential 
reduction in uptake in the putamen. ** FOCAL = focal reduction in striatal uptake 
thought to be related to previous cerebral haemorrhage. 
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Table 3-5 Post-scan diagnosis according to symmetry of predominant tremor 
type in 25 patients 
Asymmetrical 
4 PD 
1 PSP 
1 ET 
1 ET 
3 PD 
1 atypical pd 
5 ET 
1 VP or alcohol related 
Rest 
(n= 7) 
Rest & postural 
predominate 
(n= 2) 
Postural 
(n =16) 
Symmetrical 
1 PD 
1 PD 
2 ET 
1 ET + VP 
2 ET or DIP 
1 VP ± DIP 
PO = Parkinson's disease, PSP = progressive supranuclear palsy, ET = essential 
tremor, atypical PD = atypical degenerative parkinsonism, VP = vascular 
parkinsonism, DIP = drug-induced parkinsonism. 
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Table 3-6 Detailed clinical features of 25 subjects with uncertain tremor disorders undergoing [1231] FP-CIT SPECT 
Subjects are arranged according to predominant tremor type 
Patient Duration Symptoms Tremor Additional signs UPDRS Post-
(sex, (yrs) SPECT (motor) scan 
age) diagnosis 
Rest Post Predom Distribution SYM total tremor 
tremor 
type 
103 0.4 Right arm tremor Y Rest Right arm Asym Increased right wrist tone PO 
(M,61) with activation 
110 1.1 Left arm and leg Y Rest Left arm, leg Asym Reduced facial expression, 2 23 6 PO 
(M,82) tremor, generally blinking and voice volume, 
slowed, softer voice bradykinesia in left arm, 
postural instability, stooped 
. posture 
124 0.7 Unsteadiness, falls Y Rest Left leg Asym Parkinsonian gait but no 2 13 PSP 
(F,80) other definite features 
111 0.9 Speech arrest then P Rest Arms Asym Reduced facial expression, 2 31 2 PO 
(M,67) tremor right hand, impaired saccadic eye 
slowed down and stiff. movement, tone slightly 
increased in legs, positive 
palmomental reflexes 
104 0.3 Tremor left arm and Y P Rest Left arm, leg Asym Slight cogwheeling 3 7 3 PO 
(M,59) leg 
126 11 Long history of tremor Y Y Rest Arms, legs Sym Slow, shuffling gait, poor 2 51 14 PO+ ET 
(F,66) diagnosed as essential turning, stooped, rigidity and 
tremor with recent bradykinesia 
progression, falls, 
deteriorating mobility 
107 23 Mild head and hand Y Y Rest Right arm, Sym Slight postural instability, Normal 6 2 ET 
(M,65) tremor started about head reduced arm swing 
20 years ago, but 
worse in past year with 
general slowing 
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Patient Duration Symptoms Tremor Additional signs UPDRS Post-
(sex, (yrs) SPECT (motor) scan 
age) diagnosis 
Rest Post Predom Distribution SYM total tremor 
tremor 
type 
108 0.4 Arm tremor worse on Y Y Both Arms Asym Reduced facial expression Normal 5 ET 
(F,55) right and reduced blinking, 
positive frontal reflexes, 
activated rigidity right wrist 
119 2 Right arm, head and Y Y Postural Right arm Asym Jerky tremor, possible Other 24 8 Atyp PO* 
(F,75) sometimes whole body bradykinesia 
tremor, relates it to 
wide local excision of 
right breast carcinoma, 
axillary node clearance 
and radiotherapy 
109 2.1 Initially right arm then Y Y Postural Arms, legs Asym General bradykinesia and 2 39 9 PO 
(F,77) leg tremor, head rigidity 
micrographia, 
reduction in voice 
strength 
115 3.5 Tremor right arm Y Postural Right arm Asym Bradykinesia right side and 2 17 7 PO 
(M,47) worse drinking tea and rigidity on activation only, 
yawning, positive frontal reflexes, 
micrographia, has reduced arm swing on right 
noticed reduced arm 
swing. 
116 1.1 Unsteadiness on feet, Y Postural Right arm Asym Rigidity with activation both 2 15 2 PO 
(F,75) difficulty with fine hand arms, mild bradykinesia, 
movements, reduced arm swing, 
micrographia, alcohol 
improved 
102 2 Right arm and head Y Y Postural Right arm, Asym Rigidity with activation right Normal 6 5 ET 
(F,74) tremor worse on head arm 
holding cups, stiffness 
and generally slow 
105 2.6 Right greater then left Y Y Postural Arms, head Asym Normal 21 8 ET 
(F,72) arm tremor, difficulty 
with lifting cups etc 
113 Tremor left arm, Y Postural Left arm Asym Mild cogwheel rigidity right Normal ET 
(M,35) heaviness left arm and wrist and mild bradykinesia 
leg bilaterally 
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Patient Duration Symptoms Tremor Additional signs UPDRS Post-
(sex, (yrs) SPEeT (motor) scan 
age) diagnosis 
Rest Post Predom Distribution SYM total tremor 
tremor 
type 
122 10 Diagnosed with Y Y Postural Right arm, Asym Head, jaw and voice tremor, Normal 11 7 ET 
(F,75) Parkinson's for 10 head good arm swing, no rigidity 
years, tremor in lips or bradykinesia (but on 
and right hand antiparkinson medication) 
123 7.2 Right arm tremor, Y Y Postural Right arm Asym Bradykinesia right arm, Normal 21 8 VP or 
(M,64) pains in legs positive pout, broad based alcohol 
gait, dysarthria related 
117 1.1 Tremor (bilateral right Y Y Postural Arms, head Asym Mild bradykinesia in arms Normal 11 8 ET 
(F,62) worse then left), 
stiffness and slowness 
(unilateral), family 
history of tremor 
112 4.5 + Long' history of tremor Y Y Postural Arms Sym Dysphonic, bradykinetic, Normal 39 10 ET+VP 
(F,75) with positive family asymmetrical cogwheeling, 
history and alcohol shuffling gait, postural 
effect. Difficulty turning instability. Possible 
in bed, shuffling improvement with levodopa 
walking but no deterioration on 
withdrawal 
118 0.7 Tremor right hand Y Y Postural Arms Sym Rigidity and bradykinesia Normal 17 6 ETor DIP 
(F,66) worse carrying pans, both arms, positive 
micrographia palmomental reflexes 
120 5.7 Tremor left then right Y Y Postural Arms Sym Possible rigidity with Normal VP± DIP 
(F,56) arm, stiffness in arms activation and mild 
and slowness of bradykinesia left arm, 
walking, positive family positive frontal reflexes 
history for tremor, no 
alcohol effect, 
betablocker possibly 
improved 
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Patient Duration Symptoms Tremor Additional signs UPDRS Post-
(sex, (yrs) SPECT (motor) scan 
age) diagnosis 
Rest Post Predom Distribution SYM total tremor 
tremor 
type 
114 40 Tremor in fingers for Y Postural Arms Sym Postural instability, reduced Normal 8 7 ET 
(M,63) most of life, worsened arm swing on right 
recently, positive 
alcohol response & 
family history of tremor 
121 5 Tremor left arm, falls, Y Postural Arms Sym Possible bradykinesia in left Normal 4 4 ETor DIP 
(F,48) stiffness in joints, hand 
untidy writing 
Y = feature present, P = feature possibly present, BLANK = feature absent, SYM = symmetry, Asym = asymmetrical, Sym = symmetrical 
ET = essential tremor, PD = Parkinson's disease, VP = vascular parkinsonism, DIP = drug-induced parkinsonism 
PSP = progressive supranuclear palsy, Atyp PD = atypical parkinsonism 
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Table 3-7 Relationship of individual and combinations of parkinsonian signs to 
abnormal [1231] FP-CIT SPECT in a degenerative parkinsonian distribution in 
patients with uncertain tremor disorders 
Bradykinesia 
Rigidity 
Postural Instability 
Rest tremor 
Postural tremor 
Bradykinesia and Rigidity and Rest tremor 
Brain Bank criteria (part 1) 
Bradykinesia and Rigidity andlor rest tremor 
Definite Possible 
Abnormal scans I total cases with feature (%) 
12120 (60%) 6/20 (30%) 
12/17 (71%) 
5/10 (50%) 
20/38 (53%) 
12/35 (34%) 
6/10 (60%) 
0/1 (0%) 
1/2 (50%) 
2/2 (100%) 
6/8 (75%) All scored definite 
12/20 (60%) All scored definite 
14/21 (67%) Each scored either definite or possible 
Table includes all 23 patients who had abnormal SPECT in a parkinsonian 
distribution, and does not include one patient with a focal abnormality 
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Chapter 4 : [1231] FP-CIT SPECT clarifies underlying 
dopaminergic status in parkinsonism associated with 
drug use. A subgroup of the UK FP-CIT Case 
Collection 
68 
Introduction 
Drug induced parkinsonism (DIP) causes 7 - 37% of all cases of parkinsonism 
(13;231-234) which is second only to idiopathic Parkinson's disease (PD). It is found 
commonly in certain populations such as the hospitalised elderly(15} or psychiatric 
inpatient(235}. Underlying PD is present in up to 15% of cases(15;73;74;76;236;237}, 
the presence of Lewy bodies has been confirmed by post-mortem studies(236;238} 
and drug cessation only temporarily improves parkinsonian features. 
DIP can be clinically indistinguishable from PD(15;68} so that initial misdiagnosis as 
PD is common(239}. The asymmetry in clinical features which is classical of PD is 
also seen in 30 - 75% of DIP, for each of the cardinal features(66;240;241}. Rest 
tremor is typical in PD but also occurs in 44% of DIP(67}. Distinguishing features of 
DIP are: gait disturbance occurs only rarely(67;242} levodopa response is 
poor(68;243} and orofacial dyskinesia may co-exist(244}. DIP onset often coincides 
with drug prescription but can develop insidiously over years(245} and resolution 
after drug cessation rarely takes up to 18 months(71}. DIP is most often caused by 
anti psychotics or antiemetics due to post-synaptic dopamine blockade; in other cases 
e.g. valproate, less is known about the pathophysiology. 
Functional imaging of the presynaptic dopaminergic neurone in DIP 
The presynaptic dopaminergic neurone is normal in DIP with normal functional 
imaging(65; 122; 164; 186} but if imaging is abnormal it predicts clinical progression in 
keeping with degenerative parkinsonism(222}. The application of functional imaging 
to separate DIP from PD has been reported only in small mainly single centre 
studies(65; 122; 164; 186} and a UK Parkinson's Disease Society consensus report 
suggests that functional imaging may be appropriate when there is severe 
parkinsonism following neuroleptic treatment; in patients with atypical clinical 
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features, and in patients with comorbidity which might confound clinical 
diagnosis(246). 
Aims and Methods 
The design and methodology of this study is detailed in Chapter 2. This chapter 
reports on the subcategory of the UK Case Collection Study where [1231] FP-CIT 
SPECT was applied to differentiate degenerative parkinsonism (mainly Parkinson's 
disease) from drug-induced parkinsonism. Clinical features of DIP were noted in 
patients where underlying degenerative parkinsonism was excluded. Patients with 
parkinsonism were included in this diagnostic pairing if they had been exposed to 
potential dopamine-depleting drug therapy, but degenerative parkinsonism was 
considered possible on clinical grounds by the referring clinician. Further clinical 
features were requested for any of the 190 patients within the UK Case Collection 
Study with a post-scan diagnosis of DIP (i.e. not just in the pre-scan diagnostic 
pairing of DIP versus PO) which included the referring clinician's assessment of 
symmetry of clinical features, and resolution of parkinsonism with follow-up. 
Semiquantitative assessments were performed in one centre as detailed in Chapter 
2. 
Results 
Forty nine patients (27F: 22M) with mean age 62 years (SO 13; range 43 - 82) 
underwent [1231] FP-CIT SPECT in 8 centres. Patients were imaged a median of 1.5 
months after baseline characteristics were logged. Thirteen patients were on 
traditional neuroleptics, an additional 13 on atypical neuroleptics, 18 on other 
dopamine depletors (such as prochlorperazine or metoclopramide), 12 'others' (such 
as sodium valproate in 9) and 18 used antidepressants. These medicines were used 
in combination in 19 and alone in 30 patients. UK Brain Bank criteria (step 1) were 
fulfilled in 42 of 49 (86%) (bradykinesia scored definite or possible plus one other 
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feature). Baseline clinical diagnoses compared to post-scan diagnoses are 
presented in Table 4-1. SPECT gave clear results in 45 of 49 (92%) which were 
either normal or abnormal in a graded parkinsonian or focal pattern, but in 2 (4%) 
there was diffuse symmetrical markedly abnormal [1231] FP-CIT uptake, 1 (2%) had 
diffuse symmetrical mildly abnormal uptake, and 1 (2%) was borderline normal with a 
possible unilateral putamen defect. In 13 of 49 cases (27%) the initial most likely 
diagnosis did not concur with the scan findings, and clinical diagnosis was amended. 
Thirty-one patients had normal SPECT, 29 of whom had a post-scan diagnosis of 
DIP (7 with a contribution from other disorders such as cerebrovascular disease, 
essential tremor or non-PO dementia) and 2 had drug-induced tremor, while none 
had a diagnosis of degenerative parkinsonism. One had a focal abnormality on 
SPECT and a post-scan diagnosis of DIP and co-existent cerebrovascular disease. 
Semiquantative data for [1231] FP-CIT uptake in contralateral and ipsilateral putamen 
and caudate is shown in Figure 4-1 & 4-2 for 26 patients in one centre according to 
post-scan diagnosis. 
Clinical features including asymmetry and follow-up data were available in 28 of the 
32 patients with a post-scan diagnosis of drug-induced parkinsonism (without 
underlying degenerative parkinsonism). A further 2 patients with a post-scan 
diagnosis of DIP who were identified from other categories within the UK Case 
Collection Study were included, making a total of 30 patients with available detailed 
examination and follow-up data. There were 9 males and 21 females, mean age 66 
years (SO 11, range 41 - 83). Of the 30 patients, 9 had concomitant neurological 
diagnoses, as follows: cerebrovascular disease (n = 6), non-parkinson dementia (n = 
2), and essential tremor (n = 1). Bradykinesia was present in 29 (97%), rest tremor in 
21 (70%), postural tremor in 21 (70%), and 16 (53%) had both rest and postural 
components. Rigidity was present in 20 (67%) and postural instability in 9 (30%). 
Parkinsonism was asymmetrical in 21 of 30 (70%). Step 1 of the Brain Bank criteria 
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was fulfilled by 26 (87%). [123 1] FP-CIT SPECT was normal in 29 (97%) while in one 
(3%) there was a possible unilateral putamen defect. The main offending medication 
was prochlorperazine (14 of 30 cases, 47%). Sodium valproate was considered 
causative in 3 and a potential contributor with other drugs in an additional 6. Other 
drugs were metoclopramide (n = 2), amiodarone (n = 2), traditional neuroleptics (n = 
4), and atypical neuroleptics (n = 4). Melphalan was a potential cause in one, in 
whom metoclopramide was also used later. Medications were started mostly for 
depressive illness (12/30), or dizziness or vertigo (8/30); other indications included 
epilepsy, vomiting/ nausea, cardiac arrhythmia or dyspepsia. Follow-up occurred at a 
median of 10 months (interquartile range 4 -17 months) and culprit medications were 
withdrawn or reduced in 23, with complete resolution of parkinsonism in 5 patients, 
incomplete resolution in 15 and no improvement in 3. 
Discussion 
Clinical and imaging mismatch rates in drug-induced parkinsonism 
[1231] FP-CIT SPECT is useful to demonstrate underlying presynaptic dopaminergic 
deficiency in patients who present with parkinsonism with a differential diagnosis 
between drug-induced parkinsonism and Parkinson's disease. The clinicians' 
diagnosis post-scan matched in each case the scan diagnosis, and in particular no 
patients were thought to have PD with normal C23 1] FP-CIT SPECT. The mismatch 
between most-likely diagnosis pre-scan and scan diagnosis of around a quarter is in 
keeping with previous studies that suggest misdiagnosis between PD and drug-
induced parkinsonism occurs commonly. 
Misdiagnosis between PD and DIP, is confirmed by community and post-mortem 
though many of these studies tended to exclude patients on neuroleptics (so as to 
study only degenerative parkinsonism), and therefore misdiagnosis rates might be 
higher. One community study found that 12 of 402 (3%) patients with presumed PD 
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examined by hospital specialists actually had DIP instead(8), and DIP accounted for 
up to 1 % of all cases misdiagnosed as PD in post-mortem series(247). Six of 8 
patients (75%) diagnosed with DIP had alternative causes for parkinsonism identified 
pathologically which included Lewy body disease(248). Abnormal C23 1] f1-CIT SPECT 
was identified in 3 of 4 (75%) of patients with an initial pre-scan diagnosis of DIP and 
diagnoses were amended to degenerative parkinsonism (PD in 1 and PD plus in 
2)(186) but none with an initial PD diagnosis (with normal or abnormal imaging) had 
a post-scan diagnosis of DIP. Between 30%(222) and 55%(65) of patients with 
parkinsonism associated with neuroleptic use had abnormal imaging which was 
interpreted as underlying degenerative parkinsonism. Functional imaging studies 
reflect the proportion of underlying PD from a movement disorder clinic population 
(as patients are referred for imaging by movement disorder experts, not psychiatrists) 
which is more likely to see patients with more severe parkinsonism and higher clinical 
uncertainty rather than that seen in psychiatry wards where the overall proportion 
with underlying PD is likely to be lower. 
Functional imaging of the dopaminergic neurone in psychiatric disorders 
It is important to know whether an underlying psychiatric disorder is itself associated 
with an altered presynaptic dopaminergic neurone, particularly as neuroleptic naIve 
patients with first episode of psychosis have a higher prevalence of 
parkinsonism(249;250) than the general population. Further to this a change in the 
dopamine transporter due to medications for psychosis needs to be considered. 
Functional imaging studies have explored this and are summarised as follows: 
When considering schizophrenics without parkinsonism: 
Imaging in drug-naIve or previously treated schizophrenics without parkinsonism with 
[1231] FP-CIT SPECT(185) and [1231] f1-CIT SPECT(251) were found to be normal, 
however a slight decrease in striatal uptake (overlapping with control group and not 
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within the parkinsonian range) was found in chronically medicated schizophrenics 
without parkinsonism with [18F] CFT PET(252) whereas an increase was found with 
[1231] ~-CIT SPECT(253). 
In patients on neuroleptics with parkinsonism: 
Reduced striatal [1231] FP-CIT SPECT uptake was found in schizophrenics with and 
without short-term risperidone-induced parkinsonism which was significantly different 
from normals(254) but was not compared to an PD range, and the authors postulated 
that this could be related to schizophrenic disease or secondary to antipsychotic 
treatment. In severe neuroleptic induced parkinsonism functional imaging has been 
used to identify marked presynaptic dopaminergic dysfunction and dichotomize 
patients into 2 groups, the abnormal uptake group being considered to have 
. underlying degenerative parkinsonism(65;222). The only follow-up study confirmed 
that abnormal C8F] -dopa PET found in 4 of 13 patients was associated with 
progression of parkinsonism in keeping with PD unmasked by dopamine depleting 
medication whereas a normal scan predicted subsequent clinical improvement(222). 
Application of dopamine transporter imaging in clinical practice 
Regarding the application of functional imaging in patients with uncertain 
parkinsonism, there is evidence of normal dopamine transporter imaging in a small 
number of patients with a post-scan diagnosis of DIP, and none had abnormal 
imaging(122; 164; 186). 
Without C23 1] FP-CIT SPECT, withdrawal of a potential offending medication and 
monitoring will be sufficient in many cases to assess if parkinsonism is drug-induced 
or not. However improvement in some can be lengthy and in some cases underlying 
PD might not be apparent until a few years after initial clinical improvement in the 
case of drug unmasked PD. Withdrawal of psychotropic medication or trial of 
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dopaminergics or anticholinergics might sometimes exacerbate an active psychiatric 
condition or have problematic side effects. In these situations, [123 1] FP-CIT SPECT 
can prevent prolonged uncertainty or adverse medication effect. 
Clear [1231] FP-CIT SPECT result in most patients 
Scans with a borderline result between normal or abnormal may be problematic if 
numerous; however the visual assessment of [1231] FP-CIT SPECT gave a clear result 
of normal or abnormal scan in most patients and is confirmed by the semi-
quantitative data in this study which dichotomises nearly all patients with a post-scan 
diagnosis of degenerative parkinsonism and drug-induced parkinsonism. 
Borderline scan results and unmasked degenerative parkinsonism 
There were only 2 (4%) patients with borderline normal or mildly abnormal scans and 
uncertain post-scan diagnoses. As this was not a blinded study, the report of a 
'borderline' scan may have influenced the clinicians' diagnosis of an uncertain 
condition. The finding of borderline scans raises questions about the sensitivity of 
imaging. We understand the sensitivity of presynaptic dopaminergic imaging to be 
high for the dopamine transporter loss which accompanies PO, due to a preclinical 
phase of the condition before motor symptoms emerge; imaging is also abnormal in 
some asymptomatic relatives of PO patients, who are in the preclinical phase(140). 
Theoretically, however, a borderline or normal presynaptic SPECT could occur in the 
early preclinical phase of PO, in the presence of a post-synaptic dopamine blocking 
agent. This might explain our case in whom parkinsonism developed while taking 
prochlorperazine, and in whom SPECT showed a slightly reduced unilateral putamen 
uptake, matching asymmetric clinical involvement. We intend to re-scan at an 
interval in case of progressive loss of C23 1] FP-CIT uptake in keeping with PD. The 
other patient had symmetrical parkinsonism on valproate therapy, SPECT uptake 
was mildly and symmetrically reduced, and follow-up diagnosis was between a 
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Parkinson's plus disorder and valproate induced parkinsonism. We postulate that 3 
categories (DIP: definite PD: early unmasked PO) will have different [1231] FP-CIT 
uptake indices. DIP will be normal, the definite PO cases will almost certainly be 
abnormal but unmasked cases could be at the lower end of normal. 
Clinical features of drug-induced parkinsonism 
Asymmetry of parkinsonism, and rest tremor are both classical features of PD. 
Adding asymmetry to core diagnostic features in cases of parkinsonism improves 
diagnostic specificity for PD(30) and rest tremor is universally regarded as the most 
specific tremor type for PD. Our finding of asymmetry in 70% and rest tremor in 70% 
of DIP cases is similar to other reports quoting figures for asymmetry in 30% to 
58%(66-68). Unmasked PD was not excluded in these studies which might account 
for asymmetry in a proportion but the use of [1231] FP-CIT SPECT in our study helps 
reduce the risk of co-existent PO, and when dopaminergic imaging was normal, 
asymmetrical signs were identical to those with underlying PD(65). 
Although clinical asymmetry may have contributed to diagnostic uncertainty and 
therefore the selection for entry to our study, the proportion with asymmetrical 
features was similar to an unselected series(67;68). 
Tardive dyskinesia or akathisia was noted in individual cases but these features were 
not systematically recorded. These and the absence of olfactory deficit would help 
support a diagnosis of DIP. Greater characterisation of tremor into components that 
might be helpful to separate PO from DIP was beyond the scope of this project. 
Our cases are a selected series of patients who typically present to movement 
disorder clinics, and have less well recognised variants of DIP. The characteristics of 
mainly younger patients with schizophrenia who are treated in psychiatry may well 
differ from the present series; those cases are classically considered to present 
symmetrically without tremor, and to improve with anticholinergic drugs or on drug 
discontinuation. 
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Prolonged persistence of parkinsonism in drug-induced parkinsonism 
We found prolonged persistence of parkinsonism in selected cases, even after 
therapy withdrawal, which is also consistent with other studies(222;255). Incomplete 
recovery after stopping the offending medication, in the presence of normal functional 
imaging of the presynaptic dopaminergic system, has been identified in 5 of 8 
patients with normal C8F] -dopa PET followed up for a median of 12 (range 6-32) 
months(222), while two patients treated with sodium valproate and with normal [1231] 
/1-CIT SPECT had incomplete recovery at one year(255). This raises the possibility 
that some form of persistent chemical change may have been caused by the 
offending medication and that a proportion of these cases might ultimately develop 
Parkinson's disease. 
Gold-standard 
In the absence of the ideal gold standard of parkinsonism occurring with appropriate 
drug and normal brain histology, an appropriate reference for DIP would be 
parkinsonism improving after drug withdrawal. Drawbacks to this method deserve 
consideration regarding appropriate standards when offending medication cannot be 
withdrawn or in the case of incomplete improvement after drug cessation. In this 
situation [1231] FP-CIT SPECT is useful to exclude nigrostriatal degeneration, although 
as we included the SPECT result in the reference standard in this study it is possible 
that we may have overestimated its utility. For example some patients with normal 
imaging and lack of improvement after drug-withdrawal due to underlying vascular 
parkinsonism may have been inadvertently included. 
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Culprit medications in drug-induced parkinsonism 
A substantial proportion of patients considered to have drug-induced parkinsonism 
were on one or more potentially offending medications. Drug combinations increasing 
the likelihood of parkinsonism has been considered and reported previously(256) and 
the mechanisms whereby medications cause parkinsonism differ between 
drugs(257). Our study contained a surprisingly high number of patients with DIP on 
atypical anti psychotics (many were on combination therapy including valproate or 
antidepressants). Atypical anti psychotics are now a first line treatment option(258) 
because of improved tolerability (including less extrapyramidal side effects) 
compared to typical anti psychotics, however DIP is well documented to occur in 
atypicals also and the present series confirms that in the movement disorder clinic 
setting an equal number of patients being referred for imaging were on typicals and 
atypicals. Taking into account a now much larger prescription rate for atypical 
antipsychotics(259;260) because of guidelines for appropriate antipsychotic use, this 
would tend to indicate a lower risk than typicals, though it could be influenced by 
referral bias and interestingly, one recent study found the risk of drug-induced 
parkinsonism with high dose atypical antipsychotic use was comparable to that with 
traditional antipsychotics(261). 
Nine of our patients with DIP were treated with sodium valproate, an association 
highlighted in an epilepsy clinic report in which 3 of 50 consecutive patients (6%) 
were affected(255). The occurrence of reversible levodopa responsive parkinsonism 
with alkylating chemotherapy(262) has similarities to our patient with myeloma 
treated with melphalan. However, metoclopramide was also used later in the disease 
course, but his parkinsonism predated its use, raising the possibility of myeloma 
being contributory. 
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Conclusion 
This multicentre study provides evidence that it can be difficult to differentiate 
between drug-induced parkinsonism and degenerative parkinsonism clinically and 
[ 1231] FP-CIT SPECT clearly verifies the status of the dopaminergic neurones in 94%, 
with diagnostic change in line with this. The minority have borderline changes with 
diagnostic uncertainty remaining. Asymmetry of parkinsonism and rest tremor both 
occur in drug-induced parkinsonism and neither is specific for idiopathic Parkinson's 
disease. Improvement after withdrawing offending medication in cases of drug-
induced parkinsonism may be delayed, and does not necessarily indicate underlying 
PD. 
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Table 4-1 Provisional clinical diagnosis compared to post-scan diagnosis 
(made with knowledge of the [1231] FP-CIT SPECT result) in 49 patients with 
parkinsonism associated with drug use 
Baseline diagnosis Scan diagnosis Post-scan diagnosis 
PO 16 Abnormal (in PO distribution) 9 PO 7 
Progressive supranuclear palsy 1 
Lewy Body Dementia 1 
Abnormal (not PO distribution) 
Diffuse, mild symmetrical reduction PO plus and/or DIP (uncertain) 
Normal 6 DIP 5 
DIP and evidence of cerebrovascular disease 1 
DIP 33 Normal 25 DIP 17 
DIP and evidence of cerebrovascular disease 3 
DIP exacerbating ET 1 
DIP and non-PO dementia 2 
Drug-induced tremor 2 
Abnormal (in PO distribution) 4 PO 4 
Abnormal (not PO distribution) 4 
Focal lesion DIP and evidence of cerebrovascular disease 
Markedly abnormal Underlying PO or VP with DIP (uncertain) 
Markedly abnormal VPwith DIP 
Very mild asymmetrical reduction DIP: unmasked PO possible (uncertain) 
PO = Parkinson's disease, DIP = drug-induced parkinsonism, VP = vascular 
parkinsonism, ET = essential tremor 
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Figure 4-1 Semiquantitative [1231] FP-CIT uptake in putamen according to post-
scan diagnosis in patients with parkinsonism associated with drug use 
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I 
Figure 4-2 Semiquantitative [1231] FP-CIT uptake in caudate according to post-
scan diagnosis in patients with parkinsonism associated with drug use 
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For figures 4-1 and 4-2 
Upper panels: Specific: non-specific uptake ratios for contralateral and ipsilateral 
caudate according to post-scan diagnosis in 36 patients imaged in 1 centre. Lower 
panels: ratios corrected for age (for method see text), a figure of 1 is the lower limit of 
expected normal uptake. One patient with degenerative parkinsonism considered to 
be PSP is included in the PO category above. DIP cases included those with 
coexistent non-PO dementia, cerebrovascular disease or ET. 
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Chapter 5 : Prolonged follow-up of patients with 
normal [1231] FP-CIT SPECT imaging 
83 
Introduction 
The recognition of inaccuracies in the clinical diagnosis in early(6) and late(1) 
idiopathic Parkinson's disease (PD) both by community(7;8) and hospital specialists 
has led to improvement in clinical criteria(4;32), improving specificity but lowering 
sensitivity of a PD diagnosis. Diagnosis of a parkinsonian syndrome remains 
primarily dependent upon recognition of a clinical syndrome, but dopamine 
transporter imaging with [1231] FP-CIT SPECT has been shown to be sensitive and 
specific in differentiating tremor disorders fulfilling diagnostic criteria for PD and 
essential tremor (ET)(161). This has also been shown for cases not fulfilling clinical 
criteria, in whom there is increased clinical concurrence to baseline scan diagnosis at 
3 months(133) (blind to imaging results). Similar findings are reported for C23 1] I1-CIT 
SPECT at 6 months' fOllow-up(164). Additionally, presynaptic dopaminergic deficit in 
the asymptomatic striatum in patients with hemiparkinsonism(134) and in relatives of 
PD patients who later become symptomatic, suggests early sensitivity of such 
imaging(140). 
Despite this, 4 - 14% of patients diagnosed with early PD being entered into trials of 
putative neuroprotective agents had normal presynaptic dopaminergic 
imaging(127;163;212). These have been termed subjects with scans without 
evidence of dopaminergic deficiency or SWEDD's. Possible explanations include a 
lack of sensitivity of the scan in early disease, difficulty in the early diagnosis of 
idiopathic Parkinson's disease (misdiagnosis) or Parkinson's disease without 
presynaptic dopaminergic dysfunction. However, patients with normal imaging tend 
not to progress in the same way as patients with abnormal imaging and a diagnosis 
of PD, and normal imaging tends to remain abnormal when repeated after an 
interval(263). The longer term follow-up of SWEDD's with specific reference to 
clinical features, diagnosis and anti parkinson therapy response is currently 
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insufficient. Antiparkinson medication use have previously been identified in 
community studies in patients who have no clinical evidence of degenerative 
parkinsonism(7;8). However, withdrawal of antiparkinson medication in such patients 
is not reported. 
Patients in the following studies underwent SPECT imaging (with normal results) as 
part of routine clinical practice. In each subject SPECT was applied because of 
clinical uncertainty surrounding the presence or absence of underlying presynaptic 
dopaminergic deficiency. The first study: "Two year follow-up in 150 consecutive 
cases with normal dopamine transporter imaging: Experience in a regional 
movement disorders centre", primarily focuses on the longer term diagnosis of 
patients and the second study: "Successful anti parkinson medication withdrawal in 
patients with parkinsonism and normal [1231] FP-CIT SPECr, focuses on 11 patients 
who fulfilled basic idiopathic Parkinson's disease diagnostic criteria (Brain Bank 
criteria part 1) but later had anti parkinson therapy withdrawn. 
Methods 
In each study the protocol for scan acquisition was as follows. [123 1] FP-CIT with 
activity in the range 111 - 185 MBq was administered intravenously over 
approximately 15 seconds and followed by a saline flush. SPECT images were 
obtained using a dedicated multi-detector scanner (NeuroFocus Scanner, 
NeuroPhysics Corp, Shirley MA) which acquires 10 - 12 sequential single transaxial 
sections, 5mm apart, through the basal ganglia. Energy window was 140-180 keV, 
and linear attenuation correction was applied (O.008mm-1). Scanning was started and 
finished between 3 and 6 hours after administration of [1231] FP-CIT. Scans were 
reported by visual assessment as previously defined(161) by unblinded raters. Cases 
where there was focal reduction suggesting a structural lesion were included, since 
this does not indicate degenerative parkinsonism. Semiquantitative assessments 
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were performed using predetermined region of interest templates were from 
Talairach Daemon (online at http://ric.uthscsa.edu/projects/talairachdaemon.html 
assessed online 14th July 2006) and based on the Co-planar Stereotaxic Atlas of the 
Human Brain(221). Specific: non-specific ratios were calculated from three adjacent 
axial slices through the caudate and putamen. The mean specific:non-specific ratios 
were calculated from the right and left-sided reading. 
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Study 1: Two year follow-up of 150 consecutive cases with normal dopamine 
transporter imaging 
Methods 
Consecutive patients with normal [1231] FP-CIT SPECT undertaken in a regional 
neuroradiology unit from October 2000 to December 2003 were reviewed. 
Assessment during a minimum follow-up of 2 years after imaging noted clinical 
features, progression, working clinical diagnosis and use and response to 
antiparkinson medication. Case record review was supplemented whenever 
necessary by contacting the treating neurologist and/ or general practitioner. SPECT 
was applied because of clinical uncertainty about the presence or absence of 
underlying presynaptic dopaminergic deficiency. Reasons for undertaking SPECT 
were compared to suggested guidelines(246). Data are presented as mean (standard 
deviation, SD) when normally distributed, otherwise median (interquartile range, 10). 
Chi-squared analysis was used to test differences of antiparkinson therapy use 
between groups. 
Results 
Demographics 
Of 462 [1231] FP-CIT SPECT scans undertaken, 150 fulfilled the entry criteria and had 
available follow-up records (a further 30 with normal scans had incomplete follow-up 
and are not included). SPECT was requested by 16 hospital specialists and visual 
assessment was normal in 146 (97%) and focal reduction in 4 (3%). Semiquantitative 
analysis showed radioligand uptake within 2 SD of age-matched normals in all striatal 
subregions, apart from the 4 scans with a focal reduction. The mean age was 63 (SD 
12) years; 84 were female (56%) and 66 male (44%). Patients had movement 
disorder symptoms for 2.7 (10 1.3 - 5.9) years at imaging. Case note review occurred 
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2.4 (IQ 2.2 - 3.1) years after SPECT and the median follow-up duration from first 
clinic attendance was 3.2 (IQ 2.5 - 4.3) years. 
Favoured pre-scan diagnoses and reasons for uncertainty 
Whilst uncertainty occurred in all cases, the favoured documented diagnosis pre-
scan was degenerative parkinsonism in 73 (49%), non degenerative disorder in 44 
(29%) and in 33 (22%) no favoured diagnosis was documented. The commonest 
documented reasons for clinical uncertainty and [1231] FP-CIT SPECT request were 
atypical pattern of tremor (96), equivocal bradykinesia or rigidity (65), equivocal 
levodopa response (15) and severe parkinsonism whilst on dopamine depletors (16) 
and 2 or more reasons were documented for [1231] FP-CIT SPECT request in 59 
cases (39%). 
Clinical features 
The predominant disorders were tremor in 112 (75%) or gait in 18 (12%), and the 
other 20 comprised of mixed syndromes with cognitive difficulties noted in 7 of these. 
A family history of PO was noted in 13 (1 51 degree relative = 9, 2nd degree = 4); other 
tremor disorders in 20; while 2 had a family history of both PO and possible essential 
tremor. Oocumented clinical features are outlined in Table 5-1. Twenty five patients 
fulfilled part 1 United Kingdom Brain Bank criteria, while an additional 37 had 
incomplete fulfilment through the presence of only possible features. Considering the 
more specific criteria for PO, 7 patients fulfilled these through the presence of 
cardinal features, asymmetrical onset, and absence of any other possible causes of a 
parkinsonian syndrome(30). 
Antiparkinson therapy use 
Antiparkinson therapy was used in 36 (24%) (Ievodopa in 30, of whom 7 also had 
used dopamine agonists: combinations of anticholinergics, amantadine, dopamine 
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agonists and selegiline without levodopa were used in 6). This figure of 36 included 
23 of the 44 subjects (51 %) who had a pre-scan diagnosis of degenerative 
parkinsonism. Medication was used prior to SPECT in 34 cases and afterwards in 
two. Antiparkinson therapy was later withdrawn in 27 of 36 (75%), who had either no 
therapy response (10) or an uncertain or unsustained response (17) but restarted in 
two of those 27 with clinical worsening (worse UPDRS motor score in 1; during 
hospital admission with terminal acute-on-chronic liver failure and uncertain benefit in 
1). In the remaining 25 patients there was no deterioration off antiparkinson therapy. 
Antiparkinson therapy withdrawal is planned in two of the remaining cases, not 
planned in six, and not documented in one. Table 5-2 presents anti parkinson therapy 
use and effect of any withdrawal according to criteria fulfilment. Patients strictly 
fulfilling Brain Bank criteria (part 1) were more likely to undergo a trial of 
antiparkinson therapy (p < 0.05) but were no more likely to remain on, show a 
sustained response to, or try more than one type of antiparkinson therapy compared 
to those who did not fulfil criteria (overall p = 0.95). 
Structural brain imaging 
Structural brain imaging was performed in 99 (CT = 53, MR = 57, both = 11) which 
showed atrophy alone in 9, vascular changes in 40, and miscellaneous abnormalities 
in 5. Of the 4 patients with focal striatal reduction in [1231] FP-CIT uptake, only one 
had a matching vascular putamenal lesion on CT (diagnosis: VP and unclassified 
degenerative parkinsonism), repeat SPECT in the second patient became normal 
after 2.5 years (diagnosis: VP and DIP), the third had no structural disease on CT 
(diagnosis: non-degenerative parkinsonism) and the last patient with a left striatal 
focal reduction had evidence of widespread vascular disease including the right 
striatum (diagnosis: VP). 
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Diagnosis after follow-up 
The diagnosis after follow-up was non-degenerative parkinsonism or tremor in 146 
cases (Figure 5-1). In 4 patients the diagnosis was degenerative parkinsonism (1 PO, 
1 corticobasal degeneration, 2 unclassified). 
Of 150 patients, 48 are currently still under regular hospital review, 91 are 
discharged, 7 did not attend hospital appointment and 4 are known to have died. 
Discussion 
Presynaptic dopaminergic imaging is a potential adjunct to differentiate degenerative 
parkinsonism from its mimics in cases of clinical uncertainty(164;166;186;210}. It is 
abnormal in early and preclinical disease, e.g. in the asymptomatic striatum in 
unilateral PO(134-136} and in anosmic relatives of patients with PO(140}. 
Theoretically a small proportion of scans may initially be normal in patients with early 
idiopathic PO(214}, or have a normal or near-normal scan due to unmasking of PO 
by dopamine depleting drugs(219}. In our series, 3% with normal SPECT retained a 
diagnosis of degenerative parkinsonism and those cases had a 3-year symptom 
duration when SPECT was performed; none was on dopamine depleting medication. 
Repeat scanning after an interval is a possible approach in such cases. At least 
some scans should become abnormal if there is degenerative parkinsonism, since 
the progressive loss of striatal uptake in early PO is 3 to 13% per 
annum(115; 150; 151; 156;264}. Since the time period of this study we found all of 22 
normal SPECT scans which were repeated (15 through participation in a study 
protocol and 7 because of remaining clinical uncertainty) to remain normal in 21, at 
an interval of 18 (IQ 17 - 19) months. The other subject had repeat imaging at 3.3 
years when new reduced focal putamenal uptake was noted to match a vascular 
lesion on CT. Two subjects with a remaining diagnosis of degenerative parkinsonism 
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were within this group even though repeat imaging showing no evidence of emerging 
parkinsonian dopaminergic loss. 
Repeat normal imaging at up to 4 years was identified in 3 trials of anti parkinson 
therapy in between 4 and 15% of patients enrolled as early PD(162;163;212). These 
have been termed subjects with scans without evidence of dopamine deficiency 
(SWEDD's). The progressive loss of striatal uptake seen in PO is not seen in 
SWEDD's(213), and expert video review blind to scan results challenged the 
diagnosis of PO in over half the cases(216). 
Misdiagnosis also occurred in earlier clinical trials with 8.1 % of 800 patients after 8 
years' follow-up undergoing diagnostic change(6) which included non-degenerative 
disorders and was supported by post-mortem in selected cases. In 100 patients 
diagnosed clinically as PO, post-mortem examination showed misdiagnosis in 25(1) 
of whom 12 would be expected to show normal presynaptic dopaminergic imaging. 
Stricter clinical criteria would reduce the misdiagnosis rate in those with normal 
SPECT to 1 %, but at the expense of increased diagnostic uncertainty in patients with 
PD(32). 
There is however limited post-mortem verification of functional dopaminergic imaging 
results. An 80% correlation of the [1231] FP-CIT SPECT diagnosis with post-mortem 
was found in 10 patients with dementia(181). In one of the mismatch cases, a 
unilateral putamen vascular lesion was misinterpreted as early degenerative 
parkinsonism. Different patterns of abnormalities are reported in atypical 
parkinsonian disorders, for example a diffuse(224;265) rather than asymmetrical 
reduction, and caudate loss preceding putamen loss. Combining visual with 
semiquantitative assessments may help in some difficult cases, but there is always 
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going to be a small proportion of cases where the scan appearances are not 
diagnostic. 
Seven of 13 patients in our series had abnormal or borderline 02 imaging raising the 
possibility of post-synaptic parkinsonism without presynaptic abnormalities. One such 
case was considered previously(166) and abnormal 02 imaging with normal 
presynaptic imaging can be seen in Huntington's disease(266), dystonic 
conditions(267), vascular parkinsonism patients(268) and is sometimes attributed to 
neuroleptic or dopamine agonist use. The cause of abnormal 02 imaging was clear 
in only 3 of these 7 patients (neuroleptic related in 1 and vascular in 2), and the 
follow-up diagnoses were ET (1), drug induced parkinsonism (1), vascular 
parkinsonism (2), unclassified degenerative parkinsonism (1) and unknown but not 
degenerative parkinsonism (2). 
Dopamine transporter imaging results have a strong diagnostic influence(21 0), and 
for this reason we conducted longer term follow-up, to seek any evidence of 
emerging degenerative parkinsonism. Our results agree with blinded studies in 
uncertain parkinsonism, in which there is increased congruence with a baseline scan 
result over 3(133) to 6(164) months. In our series 8 (5%), of whom 6 were clinically 
thought to be benign disorders and 2 to have degenerative parkinsonism, did not 
obtain a definitive diagnosis during follow-up. Unclassifiable parkinsonism at a rate 
of 4 - 5% in specialist clinics was reported before(269), and poor or equivocal 
response to anti parkinson medication was the main reason for uncertainty. 
The therapeutic approach in patients with normal [1231] FP-CIT SPECT and clinical 
features of a movement disorder is worth review. Firstly, to identify clinical features of 
patients who may have a false-negative scan, i.e. where idiopathic or degenerative 
parkinsonism is present, and benefit might accrue from antiparkinson therapy. 
Secondly, to assess what proportion of cases are commenced on anti parkinson 
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therapy, the clinical response, and effects of any withdrawal. Patients strictly fulfilling 
Brain Bank criteria (part 1) were more likely to undergo a trial of anti parkinson 
therapy but were no more likely to remain on therapy compared to those who did not 
fulfil criteria. The results suggest a closer correlation between [1231] FP-CIT SPECT 
and therapy response than with criteria fulfilment, but require comparative data from 
patients with abnormal scans. 
Documented reasons for referral for [1231] FP-CIT SPECT in our study concurred with 
suggested guidelines(246). 
Conclusion 
The emerging clinical profile of lack of clinical progression in line with degenerative 
parkinsonism and lack of response to anti parkinson medication or repeat normal [1231] 
FP-CIT SPECT imaging where this has been applied suggests that nearly all patients 
with normal baseline [1231] FP-CIT SPECT scan have a benign movement disorder 
rather than degenerative parkinsonism. A subset of patients with normal [1231] FP-CIT 
SPECT fulfils clinical criteria for PO, but even in these cases there is negligible 
response to antiparkinson therapy, which is therefore seldom maintained. 
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Figure 5-1 Final clinical diagnosis after follow-up in 150 patients with normal 
[ 1231] FP-CIT SPECT 
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Table 5-1 Presence and certainty of cardinal parkinsonian features in 150 
patients with normal [1231] FP-CIT SPECT 
Bradykinesia 
Rigidity 
Tremor 
Postural 
instability 
Rest only 
Postural only 
Rest and 
postural 
Definite Possible 
29 41 
36 31 
10 0 
43 0 
62 1 
16 7 
one site only, e.g. reduced arm 
swing n = 31 
an additional 2 had spasticity and 1 
had myotonia 
Table 5-2 Antiparkinson medication use in 150 patients with normal [1231] FP-
CIT SPECT, according to presence of definite clinical features 
Criteria (total number fulfilling) 
Brain Bank criteria part 1 (25) 
Brain Bank part 1 plus asymmetry + no exclusions (7) 
Bradykinesia plus rigidity & rest tremor (11) 
Antiparkinson therapy use 
(used and maintained, used and worse on 
withdrawal, used and stopped without 
deterioration, never used) 
2,0,9,14 
1,0,0,6 
2,0,4,5 
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Study 2: Successful antiparkinson medication withdrawal in patients with 
parkinsonism and normal [1231] FP-CIT SPECT 
Methods 
Cases with parkinsonism, normal [1231] FP-CIT SPECT imaging and prior use of 
antiparkinson medication were identified by two methods: 
1) prospectively screening cases attending the movement disorder clinic over a 2-
year period 
2) retrospective review of 462 patients with diagnostic uncertainty who underwent 
C23 1] FP-CIT SPECT from November 2000 to December 2003 from the radiology 
database. 
Three movement disorder specialists (VM, KG, DG) ascertained clinical features and 
criteria fulfilment and therapy response from a combination of clinical and case note 
review. All patients had attended movement disorder specialists. Parkinsonism was 
defined according to the Parkinson's Disease Society Brain Research Centre of the 
United Kingdom(30) and required the presence of bradykinesia and at least one of 
the following: 4 - 6 Hz rest tremor, rigidity, or postural instability not caused by 
primary visual, vestibular, cerebellar or proprioceptive dysfunction. Classification was 
performed for tremor disorders(53), other degenerative parkinsonian syndromes(33) 
and vascular parkinsonism(56) using published criteria. Antiparkinson medication 
response was graded based on a previously reported method(57). Response was 
categorised as excellent if described as "dramatic", "excellent", or "spectacular"; good 
if motor symptoms improved substantially; moderate where "modest" or "moderate" 
were used and absent when no useful response was documented. Effect of 
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antiparkinson therapy withdrawal was noted as "deterioration", "possible 
deterioration" or "no deterioration". 
Levodopa dose equivalents were calculated using published theoretical equivalent 
data(270) as follows: 
levodopa dose + bromocriptine (mg) x 10 + cabergoline or pramipexole (mg) x 67 + 
ropinirole (mg) x 20 + pergolide (mg) x 100 + apomorphine (mg) x 8. We placed the 
levodopa equivalence of selegiline 5 or 10mg at 100mg. 
Results 
Demographics 
Eleven patients, 6 men and 5 women, mean age 65 years (SO 8) were identified. 
Mean symptom duration p~ior to SPECT was 5.6 years (SO 3.4, range 2 - 13). In 10 
of the 11 cases, clinical features were tremor-predominant (Table 5-3). A clinical 
diagnosis of PO (by a hospital specialist) was documented in 7 of the 11 cases, while 
3 were considered to have an atypical tremor disorder, and one had features of 
vascular parkinsonism and/ or PO. 
Antiparkinson therapy response, withdrawal and clinical features 
Antiparkinson medication was prescribed (by hospital specialist in all 11 cases) for a 
median of 7 months (10 2 - 11). The cumulative levodopa equivalent dose per patient 
was 20g (10 11 - 100g). [1231] FP-CIT SPECT was normal by visual assessment and 
the uptake ratios for caudate and putamen (contralateral and ipsilateral) were within 
2 SO's of age matched normal controls. [1231] FP-CIT SPECT was normal on repeat in 
2 patients after 7 and 36 months. There was no antiparkinson medication response in 
9 cases, but a positive initial response in 2 (excellent levodopa response at 300mg 
per day over 84 months in one; moderate response to ropinirole 3 mg per day over 
12 months in the other) - cases 7 and 9. Ouring follow-up, 8 cases failed Brain Bank 
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exclusions (Step 2 of criteria), mainly through emerging evidence of an absent 
levodopa response and remaining unilateral, while 4 failed Brain Bank prospective 
criteria (Step 3). Although 3 cases continued to fulfill all 3 steps of the Brain Bank 
criteria, a lack of progression and normal [1231] FP-CIT scans raised sufficient doubt to 
justify stopping therapy. Follow-up was for a minimum of 1 year (median 3 years, 10 
2 - 4) after antiparkinson therapy withdrawal, which was not associated with any 
clinical deterioration. 
Discussion 
Antiparkinson therapy withdrawal in patients with clinical features of parkinsonism 
and normal presynaptic dopaminergic imaging is previously unreported. Our cases 
would have qualified at presentation for entry into clinical trials of antiparkinson 
medication such as the 3 recent studies(163;211 ;212) in each of which patients 
termed SWEDD's were identified. During this period, 282 patients had abnormal 
imaging, so the rate of SWEDD's amongst cases with abnormal scan was 4%. 
Expert blinded video review of SWEDD's, disputed a PD diagnosis in 54%, but 
consideration to alternative diagnoses was not given(216). Seven of our patients 
would be classified with follow-up as indeterminate tremor syndrome(53), in which 
essential tremor is accompanied by some features of parkinsonism (e.g. hypomimia, 
reduced arm swing, mild bradykinesia). 
The experience of treatment benefits in SWEDD patients in the recent studies has 
been variable, but was well documented by repeat UPDRS measurements. In the 2 
trials comparing a dopamine agonist with levodopa, the therapy response was similar 
in SWEDD patients to those with abnormal scans(211 ;212). In the ELLDOPA study, 
even high dose levodopa did not improve SWEDD cases(163). One explanation may 
be the inclusion of a placebo arm in ELLDOPA but not in the other studies, which 
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influenced interpretation of therapy effects. Lack of response to anti parkinson therapy 
contributes significantly to evolving uncertainty about an initial PD diagnosis(269), 
and was a main contributor in our cases. Starting antiparkinson medication early has 
received some recent support(271), which may necessitate diagnostic revision and 
therapy withdrawal more than is currently practised. 
The documented benefit from anti parkinson therapy in 2 of our cases is significant as 
a trial of therapy can aid the diagnostic process, but is subjective. A false-positive 
response is likely, since later therapy withdrawal did not cause deterioration. A false-
positive levodopa response can occur in patients thought to have PD during life but 
having no post-mortem evidence of degenerative parkinsonism(3). A positive 
response to anti parkinson therapy in some cases of vascular parkinsonism is 
documented(57), but has not been subjected to placebo controlled evaluation. While 
acute challenges (apomorphine or levodopa) have low sensitivity and specificity 
especially in early disease, a formalized protocol for the out-patient approach has, 
perhaps surprisingly, not been developed, and would benefit future work of this type. 
In vascular parkinsonism, escalating levodopa to 19 daily is suggested(57), but is not 
widespread practice. Our definition of therapy response, and the doses of 
antiparkinson medication used, are limitations, but used established methodology. 
Moreover, the evolving clinical picture in conjunction with normal dopaminergic 
imaging is more in favour of an inaccurate baseline diagnosis. Some non-specific 
therapy effects may influence interpretation of the diagnostic response: levodopa 
speeds reaction time to sensorimotor tasks(272); pramipexole improves depression 
even in the absence of PD(273). 
Conclusion 
In conclusion, this report identifies a subset of patients initially diagnosed as 
idiopathic PD, but in whom antiparkinson therapy was later withdrawn without 
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deterioration. The emerging profile of such patients, all of whom had normal 
presynaptic dopaminergic imaging, differs significantly from idiopathic PD. Vigilance 
regarding the likely presence of such cases is important in clinical practice and 
clinical trials. 
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Table 5-3 Clinical features of 11 patients with normal [1231] FP-CIT SPECT 
treated with anti parkinson medication which was later successfully withdrawn 
Patient Symptom Clinical features H&Y Antiparkinson 
Age (sex) duration medications 
(years) 
1.58 yrs (m) 3 Asymmetrical rest, postural & action tremor, & rigidity on co- 2.5 Levodopa> 100mg/d, 
activation, reduced arm swing, stooped, slight postural Pramipexole 0.375mg/d 
instability. MR brain - cerebrovascular disease 8 months 
2.62 yrs (f) 6 Hemibody rest and postural tremor, mild bradykinesia, reduced Levodopa 150mg/d 
arm swing. Postural instability 12 months 
3. 60 yrs (f) 8 Unilateral reduced movement with foot dragging. Possible Levodopa > 100mg/d 
bradykinesia and cogwheeling. MR brain - normal 1 month (intolerant) 
4. 68 yrs (f) 6 Slightly asymmetrical rest tremor in parkinsonian range, 2 Levodopa 300mg/d 
symmetrical postural tremor with bradykinesia, reduced arm 10 months 
swing 
5. 70 yrs (f) 9 Bilateral postural arm tremor. New signs of rest tremor, 2.5 Levodopa 400mg/d 
hypomimia, cogwheeling, bradykinesia and reduced arm swing 12 months 
6.66 yrs (m) 3 Asymmetrical arm rest tremor and leg tremor on standing. 2 Levodopa> 100mg/d 
Bilateral postural tremor with bradykinesia & hypomimia. CT 3 months 
brain - atrophy 
7.68 yrs (m) 3 Jerky & asymmetrical rest, postural and action tremor, possible 2 Ropinirole 3mg/d 
rigidity & bradykinesia. Progressive. CT brain - cerebrovascular 12 months 
disease 
8.60 yrs (m) 3 Asymmetrical rest, postural & action tremor, hypomimia, slight 2 Levodopa 50mg/d 
bradykinesia, reduced arm swing 3 months 
9.55 yrs (m) 13 Asymmetrical rest, postural & action tremor, cogwheeling and 2 Levodopa 
possible bradykinesia. CT brain - normal 300mg/d 84 months 
10.84 yrs (m) 2 Asymmetrical postural & action tremor, rigidity, possible 3 Levodopa 100mg/d 
bradykinesia, short steppage, postural instability, slow turning 7 months 
gait. CT brain - cerebrovascular disease 
11. 62 yrs (f) 7 Unilateral onset rest & postural tremor, possible bradykinesia, 2 Levodopa 300mg/d 
reduced arm swing 1.5 months 
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Chapter 6 : Parkinson's Disease is overdiagnosed 
clinically: a 3-year European Study with repeat [1231] 
FP-CIT SPECT 
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Introduction 
The misdiagnosis of idiopathic Parkinson's disease (PO) is recognized in many 
settings. A PO diagnosis is still dependent upon the clinical recognition of 
asymmetrical parkinsonism responsive to antiparkinson therapy, and no diagnostic 
test is specific to idiopathic PD. 
The difficulty with clinical separation of PO and essential tremor (ET)(7;8) can be 
attributed in some circumstances to uncertain presence of parkinsonian features or 
atypical presentations of PD such as with postural tremor(21), whilst in ET the 
occurrence of asymmetry(274), rest tremor(229), cogwheeling or the co-existence of 
soft parkinsonian features particularly in elderly populations(27S) may all contribute. 
In post-mortem series(1 ;32), other types of degenerative parkinsonism (e.g. multiple 
system atrophy, progressive supranuclear palsy or corticobasal degeneration), 
Alzheimer's disease, and vascular parkinsonism are most commonly misdiagnosed 
as PD. Specific prognostic information exists for each of these, and correct diagnosis 
limits unnecessary and inappropriate medication. 
Misdiagnosis is more common in non-specialist settings(8;164), and the highest 
clinical diagnostic accuracy is accredited to movement disorder specialists(4;6;164). 
Even so, some consider that 4 -14% of patients entered as early PO in 
neuroprotective studies(163;211 ;212) by movement disorder specialists who have 
normal imaging of the presynaptic dopaminergic neurone have been misdiagnosed 
as PO(164), whilst others believe that low sensitivity of dopaminergic imaging or a 
form of degenerative parkinsonism not associated with striatal dopaminergic 
neuronal loss is more Iikely(227). So far, the final diagnosis of these SWEDO's 
(subjects with scans without evidence of dopaminergic deficiency) is unknown. 
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Dopamine transporter imaging of the presynaptic dopaminergic neurone is an 
established accurate method to differentiate between subjects fulfilling PO or ET 
criteria(161; 162), but few blinded imaging studies assess precision of dopamine 
transporter imaging in early, uncertain parkinsonian conditions(164), and none has 
longer term follow-up. 
We aimed to determine the accuracy of dopamine transporter imaging to differentiate 
between degenerative parkinsonism (mostly PO) and its non-degenerative tremor 
mimics (mostly ET) by assessment of serial imaging and clinical assessments over 3 
years. Follow-up of previously reported 3 month data(133) is reported here, along 
with additional cases from extension of the study to multiple centres. 
Methods 
Patients of either sex aged 30 to 90 years were included if there was clinical 
uncertainty about their diagnosis. Patients were recruited from the following centres: 
Glasgow, Wolverhampton, Southampton and Newcastle (UK);Marburg (Germany); 
Coimbra (Portugal); Yvoir (Belgium) and 2 sites in Barcelona (Spain). Fulfilment of 
UK Brain Bank criteria step 1 (30) and Findley and Koller criteria for definite or 
probable essential tremor(276) was recorded. Diagnostically certain cases were 
excluded (e.g. positive response to dopaminergic therapy, clinical history over 5 
years). The Unified Parkinson's Disease Rating Scale (UPDRS) part III (motor) score 
at entry was prespecified as s 16. Subjects gave written informed consent and the 
study had Ethics Committee approval. Patients with other potential causes of 
parkinsonism/ tremor were excluded (cerebrovascular disease, structural brain 
lesion, psychiatric illness other than depression, dementia, head injury, neuroleptic 
use at symptom onset; features of multiple system atrophy or progressive 
supranuclear palsy, hyperthyroidism, tremorogenic medication). Patients with major 
comorbid illness or iodine sensitivity were also excluded. 
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Imaging with [123 1] FP-CIT SPECT occurred at t = 0, 18 and 36 months. On-site 
clinical diagnosis, UPDRS and Hoehn & Yahr (H & Y) scores (12 hours off 
parkinsonian medications) blind to SPECT result were noted at t = ° and t = 3 
months and repeated unblinded to SPECT result at 18 and 36 months. 
A video recording of UPDRS part III taken after 12 hours off medication at t = 36 
months was scored by 2 independent assessors blind to SPECT and working clinical 
diagnosis. Subject-specific information was provided: a description of symptom 
onset, results of structural cranial imaging, on-site findings for UPDRS rigidity, H & Y 
score, and medication use. Any disagreement was reviewed and the consensus 
agreement at t = 36 months was defined as the "consensus video diagnosis" and 
was the gold-standard. 
Imaging procedures 
[123 1] FP-CIT SPECT was performed according to established protocol in each centre. 
Dopaminergic and other medications were continued except for agents interfering 
with striatal [1231] FP-CIT uptake (e.g. central nervous system stimulants, anti-
anorexia and obesity treatments, sympathomimetics) which were stopped for at least 
4 weeks. Each subject received a thyroid blocking preparation and a single slow 
intravenous injection of C231] FP-CIT (N-w-fluoropropyl-2~-carbomethoxy-3~-[4-
iodophenyl]nortropane) at between 111-185 MBq (3-5mCi). Images were acquired 3 
to 6 hours after injection using either a multi-detector single slice system or multi-
headed gamma cameras (both capable of SPECT acquisition, reconstruction, and 
producing transverse slices with a clear visualisation of the striatum). 
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Data processing 
[123 1] FP-CIT SPECT scans were evaluated by an on-site reader, and also by three 
independent nuclear physicians. Readers were experienced in scan reporting, and 
knew the subject's age but not other clinical details. Visual assessment graded 
scans as: normal largely symmetrical in putamen and caudate; abnormal grade 1 
asymmetrically reduced putamen activity; abnormal grade 2 significant bilaterally 
reduced putamen uptake, activity confined to the caudate; and abnormal grade 3 
virtually absent uptake bilaterally affecting both putamen and caudate nuclei(161); or 
as other when not defined by one of these categories. Scans were divided into 2 
groups: normal or abnormal (corresponding to grade 1, 2 or 3, or 'other'). Scans with 
movement artefact or reconstruction problems prohibiting interpretation were 
excluded from analysis. Predefined options for clinical diagnosis were: early probable 
PO fulfilling Brain Bank criteria step 1; early possible PO not fulfilling Brain Bank 
criteria step 1; possible ET, benign tremulous PO, or other. 
To compare [1231] FP-CIT SPECT results with the consensus video diagnosis, the 
clinical diagnosis was considered degenerative parkinsonism (which should 
correspond to an abnormal SPECT image) or non-degenerative parkinsonism (where 
SPECT should be normal). Probable PO, possible PO, and benign tremulous PO, 
multiple system atrophy and progressive supranuclear palsy were all categorised as 
degenerative parkinsonism. ET, dystonic tremor, and vascular parkinsonism were 
classified as non-degenerative parkinsonism. The efficacy of [1231] FP-CIT SPECT in 
the differentiation of early degenerative parkinsonism from other forms of tremor (e.g. 
ET) was assessed by comparing the results of the visual assessment of [1231] FP-CIT 
SPECT images at t = 0 with the consensus video diagnosis. 
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Two-hundred and two subjects were screened (including 3 age-matched healthy 
volunteers). The efficacy population (patients who completed imaging at 3 time points 
and with a video consensus report at t = 36) consisted of 99 subjects (Figure 6-1). 
Statistics 
Continuous variables were summarised by descriptive statistics. Statistical tests were 
carried out at the 5% level of significance, unless otherwise specified. The 
calculations of positive predictive value (PPV), negative predictive value (NPV), 
sensitivity, specificity and accuracy were calculated as follows: 
Gold standard 
(video assessment) 
Read of [1231] FP-CIT SPECT images 
Abnormal (degenerative 
parkinsonism) 
Abnormal (degenerative True positive (TP) 
parkinsonism) 
Normal (non- False positive (FP) 
degenerative 
parkinsonism) 
Normal (non-
degenerative 
parkinsonism) 
False negative (FN) 
True negative (TN) 
PPV = TP!(TP + FP): NPV = TN!(FN + TN): Sensitivity = TP!(TP + FN): Specificity = 
TN!(TN + FP): Accuracy = (TP + TN)! (TP + FP + TN + FN) 
Efficacy population 
Subjects were included in the efficacy population when both the [1231] FP-CIT SPECT 
at t = 0 and the clinical consensus diagnosis (gold standard) at t = 36 video were 
available (Figure 6-1). 
The primary endpoint was a comparison of the t = 0 SPECT scan reading to the 
consensus clinical diagnosis from video at t = 36 months. Secondary endpoints 
included a comparison for each imaging endpoint to the on-site clinical diagnosis at t 
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= 18 and t = 36 months. Co hens Kappa coefficients were calculated to assess inter-
reader agreement between [1231] FP-CIT SPECT readers (both on-site and 
independent) between all normal and abnormal imaging findings at each imaging 
time point. Kappa coefficients were calculated for agreement between the 
independent inter-video readers at t = 18 and 36 months of a diagnosis of 
degenerative parkinsonism or non-degenerative parkinsonism diagnosis and 
included all available subjects at each time point. Chi squared testing was used to 
compare levels diagnostic disagreement between video readers in patients where 
clinical and imaging data matched versus patients where clinical and imaging data 
did not match. Two-tailed paired t-tests were used to assess significance of change 
of UPORS motor scoring from 0 to 36 months. 
Results 
Baseline demographic and clinical data is shown in Table 6-1 according to the gold 
standard diagnosis at 36 months. There were 71 subjects with a gold-standard 
diagnosis of degenerative parkinsonism (66 classified as probable PO who fulfilled 
Brain Bank criteria step 1, and 5 with possible PO who did not fulfill criteria). Baseline 
C23 1] FP-CIT SPECT was abnormal in 56 of 66 (85%) classified as probable PO but 
was normal in the 5 classified as possible PO at 36 month video diagnosis. Twenty-
eight subjects were classified as non-degenerative parkinsonism of whom 1 (4%) had 
abnormal imaging. 
Baseline and 3 year motor scoring and antiparkinson medication use is categorized 
according to 3 year consensus video diagnosis (Table 6-2) and baseline imaging 
result (Table 6-3). The increase in motor score (UPORS) over 3 years was significant 
in patients with a consensus video diagnosis of probable PO (p < 0.0001), but did not 
reach significance in those diagnosed as possible PO or non-degenerative 
parkinsonism! tremor (Table 6-4). When categorized according to baseline imaging 
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(abnormal or normal), a significant increase in UPORS was found for both abnormals 
(+10.2, SO 10.5, P < 0.0001) and normals (+2.3, SO 7.0, P = 0.04). Similarly, the 
number of subjects on antiparkinson medication increased by 27% in those with a 
probable PO diagnosis, but did not increase in those with possible PO or those with 
non-degenerative parkinsonism, whilst the increase was 30% for abnormal and 2% 
for normal baseline imaging. 
The sensitivity of the independent SPECT read at t = 0 months compared to the 3-
year gold-standard diagnosis ranged from 77.5 to 78.5% and the specificity was 
96.6% for all 3 readers (Table 6-5). For the on-site clinical diagnosis (blinded to 
SPECT results) at t = 0 the sensitivity was 93% and the specificity was 46.3% 
compared to the gold standard. Fifteen of 81 patients (18%) with an on-site PO 
diagnosis at baseline were assessed as non-degenerative parkinsonism (mostly 
essential tremor! benign tremor disorders) by the 3-year gold-standard. Fourteen of 
these 15 had normal baseline SPECr. Five of 18 (28%) with an on-site non-
degenerative parkinsonism diagnosis at baseline were assessed as PO by the 3-year 
gold-standard. Two of these 5 had abnormal baseline SPECT (Table 6-6). 
Inter-reader agreement between SPEeT readers 
Combined kappa coefficients for all independent SPECT readers were 0.97 (CI 0.88 
to 1) at t = 0; 0.94 (CI 0.84 to 1) at t = 18; and 0.97 (CI 0.85 to 1) at t = 36. Between 
on-site SPECT readers and independent readers kappa coefficients were lower at 
each time point, ranging from 0.82 to 0.96. 
Inter-reader agreement between video readers at t = 18 and t = 36 
At t =18 months, 23 of 122 videos (19%) assessed by both readers were diagnosed 
differently, which gave a kappa coefficient of 0.37 (CI 0.17 to 0.58). At t = 36, 13 of 
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99 videos (13%) were diagnosed differently, with a kappa coefficient of 0.68 (CI 0.53 
to 0.83). 
Discussion 
Parkinson's disease was over-diagnosed clinically at baseline in this series, when 
compared to the gold standard of the consensus video diagnosis after 3 years. 
Eighteen percent of patients with a baseline PO diagnosis were revised to a 
diagnosis of non-degenerative parkinsonism at 3 years, and most of those (93%) had 
a normal baseline SPECT. In contrast, the specificity of baseline SPECT was higher 
than baseline clinical diagnosis, as only 2% with abnormal SPECT at t = 0 had a non-
degenerative diagnosis at 3 years. This clinical over-diagnosis of PO has been found 
in 15 to 47% of cases within the community(7;8) and in hospital studies where post-
mortem confirmation of non-PO diagnoses occurred in 10 to 24%(1 ;32;247;277). 
Other types of degenerative parkinsonism accounted for around a half of these 
misdiagnoses, while non-degenerative diagnoses were primarily vascular 
parkinsonism, Alzheimer's disease and non-parkinsonian tremor disorders. As we did 
not differentiate in our gold standard between different types of degenerative 
parkinsonism (as SPECT would be abnormal in all), our study might actually 
underestimate the over-diagnosis of PO (e.g. for MSA). However, subjects with 
tremor disorders were deliberately targeted for entry into this study and patients with 
features suggesting atypical parkinsonism were excluded, which would be expected 
to reduce the number of cases of PSP, MSA or CBO. The positive predictive value of 
an abnormal baseline SPECT is therefore higher than that of the baseline clinical 
diagnosis. 
Only one case would be considered a 'false positive' result from [1231] FP-CIT SPECT 
according to gold-standard diagnosis. This patient did not have any movement 
disorder features in the 3-year video assessment and had abnormal baseline and 
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subsequent [1231] FP-CIT SPECT (graded 2 and 3). This 37 year old had a baseline H 
& Y of 1.5 with UPDRS (motor subscore) of 11, 5 and 8 at t = 0, 18 and 36 months 
respectively and was on a dopamine agonist. On-site clinical diagnosis was 
degenerative parkinsonism throughout. This raises the possibility that the gold 
standard diagnosis was incorrect, perhaps because of mild signs masked by 
anti parkinson medication. 
While baseline imaging was highly specific for degenerative parkinsonism according 
to the consensus video diagnosis, the sensitivity is lower (77 - 80%) in this study of 
early parkinsonism compared to those with a definite diagnosis fulfilling clinical 
criteria (97 - 98%)(161;162). In the current study a gold-standard diagnosis of 
degenerative parkinsonism occurred in conjunction with normal imaging in 15 of 71 
subjects (21 %), a population that we consider similar to "SWEDD's", which were 
initially recognized in a notable proportion of subjects entered as PD into 3 large 
trials(147;211 ;212). Potential reasons for this 'mismatch' between clinical and 
imaging findings include an incorrect gold standard diagnosis, poor sensitivity of 
functional imaging to nigrostriatal degeneration, or an undescribed form of 
degenerative parkinsonism without striatal cell loss. These are now considered. 
The videotaped examination is imperfect, but was necessary to allow the treating 
clinician access to the SPECT results. The sensitivity of clinical video-diagnosis in 
parkinsonism was 86 - 91 % and specificity 98 - 100%(278;279) against identification 
of normal adults. Lower sensitivity was noted in milder! shorter duration 
disease(279), which includes at least a proportion of our cases and is in keeping with 
the observation that agreement between our video raters improved from 18 to 36 
months. Additionally, the video-rater was aware of anti parkinson therapy, which was 
considered necessary to interpret signs in the context of prevailing therapy. Given the 
on-site clinical overdiagnosis of PD, and the associated use of antiparkinson therapy, 
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the gOld-standard diagnosis may therefore have been biased towards a PO 
diagnosis. The alternative of a blinded clinical examiner might prove more definitive. 
If the imaging technique had low sensitivity, the annual 7 to 14% loss of uptake in PO 
suggests that some normal images would become abnormal over time. In SWEOO's 
from REAL PET, CALM-PO and ELLOOPA(147;211 ;212) imaging remained 
repeatedly normal at up to 4 years and serial semiquantitative measurements shows 
no reduction(213). 
The consensus report of imaging at t = 0 for the 15 SWEOO patients was of normal 
uptake, however 31 15 had the report of 'abnormal' at least once by one or more 
reporters and in 1 case the consensus opinion of the SPECT readers graded this 
scan at t = 36 months as abnormal (grade 1 with asymmetrically reduced putamen 
uptake). This patient had a UPORS III of 1,3 at t = 0, 12 at t = 18, and 17 at t = 36 
months and had a predominantly symmetrical akinetic-rigid syndrome. There was 
additional uncertainty in the video-rating, which considered vascular 
pseudoparkinsonism and multiple system atrophy. The patient was not on any 
medications known to interfere with the dopamine system. The possibility of normal 
early imaging in some forms of degenerative parkinsonism is raised by another report 
of a post-mortem verified case of corticobasal degeneration with normal radioligand 
uptake(181). In another study (without dopaminergic imaging) 2 patients had post-
mortem verified "minimal change" multiple system atrophy restricted to the substantia 
nigra (without striatal cell loss)(280). Functional imaging would likely be normal in 
such cases, although this is rare amongst cases of MSA(34). "Minimal change" PO 
has not been reported in functional imaging studies; although the Braak(23) 
hypothesis suggests this might occur at a very early clinical stage, this applies to pre-
motor presentations of PO, which are also uncommon, and progression to striatal 
loss and motor features is considered inevitable. 
112 
The present study adds to the limited clinical information available regarding 
SWEOO's. The inverse relationship between the duration of symptoms and the 
proportion of SWEOO's(215} argues against a persistently non-nigral form of PO in 
which the proportion would remain constant. In our study, SWEOO's decline from 
31 % at baseline (and symptom duration of 3.3 years) to 21 % after 3 years (symptom 
duration of 6.3 years). This is notably higher than rates of 14% of SWEOO's (mean 
disease duration 6.5 months) in ELLOOPA(163}, 11% SWEOO's (16 months' 
duration) in REAL-PET(212}, 4% SWEOO's (18 months' duration) in CALM-PO(216}, 
and 1.4% (23 months' duration) in NIL-A-CIT(215}. One explanation is that this study 
is representative of a population of uncertain parkinsonism/ tremor disorders with 
potentially higher rates of misdiagnosis. 
Of the 15 SWEOO patients at t = 36, 12 had a baseline PO diagnosis and another 3 
patients were not classified as PO at baseline. The on-site clinician disagreed with a 
PO diagnosis in 8 of 15 of these SWEOO's at t = 36 but bias had been introduced 
through awareness of SPECT result. Agreement rates between video readers (at 36 
months) were lower in SWEOO's (disagreement between a degenerative and a non-
degenerative disorder occurred in 4 of 15, 27%) compared to those with the expected 
abnormal scan result (2 of 56, 4%) whereas average confidence of a degenerative 
parkinsonian diagnosis at t = 36 months was lower in subjects with unexpected 
normal imaging at 72% compared to those with expected abnormal imaging at 92%. 
Antiparkinson medication was not used over 3 years in 7 of these 15 SWEOO 
patients (47%) over 3 years which is surprising given the mean disease duration of 
6.3 years (it was never used in 7 of 56 patients (12%) with a PO diagnosis and 
abnormal imaging and mean disease duration of 5 years)(163) A non-significant 
increase in UPORS (motor) of an average 5 points (SO 10) over 3 years contrasts to 
the significant increase seen with subjects with expected abnormal imaging. Further 
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to this, it is notable that the SWEOO population had a positive family history of tremor 
disorder in 67% (versus 19% for subjects with baseline abnormal SPECT imaging), 
and an alcohol response was noted in 7% (versus 5% for those with abnormal 
imaging). 
The final diagnosis of the SWEOO population cannot be answered by this study, 
however, we find evidence that SWEOO's have a different imaging and clinical 
course to those with degenerative parkinsonism and imaging evidence of dopamine 
deficit and this is supported by observations in other studies of poor levodopa 
response(163), lack of progression in sequential dopaminergic imaging(213), and 
consideration that a PO diagnosis is unlikely in over half of SWEOO's after 
consensus panel video review(216). 
We have demonstrated a very high interrater agreement between scan reports (of· 
normal or abnormal) confirmed by the high Kappa coefficients for the SPECT readers 
which is important in clinical practice. And the notable stability of sensitivity and 
specificity of the independent blinded SPECT at each time point compared to the 
gold-standard diagnosis (Table 6-6) results from imaging that remains normal or 
abnormal in most cases. 
Conclusion 
PO was overdiagnosed clinically in this series. The gold-standard clinical diagnosis 
(at 3 years) indicates a high specificity for baseline [1231] FP-CIT SPECT, suggesting 
that combining clinical and imaging assessments could reduce overdiagnosis of PO 
in this category of patients. A fifth of patients with a 3 - year diagnosis of 
degenerative parkinsonism had normal scans; their clinical and imaging course 
differs from that expected with degenerative parkinsonism. 
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Figure 6-1 Disposition of subjects within the 3 year study of accuracy of [1231] 
FP-CIT SPECT in early and uncertain parkinsonianl tremor disorders 
Enrolled: 202 subjects 
23 subjects withdraw n (subject request 14, violation of 
iteria 8, symptom 1) inclusion/exclusion cr 
t = 0 Imaging: 179 subjects 
52 subjects withdraw n (lost to follow-up 28, subject request 
protocol violation 2) 18, safety reason 4, 
t = 18 Imaging: 127 subjects 
28 subjects withdraw n (subject request 14, protocol violation 2, 
o follow-up 4, entry criteria 2, other 1) safety reason 5, lost t 
t = 36 Imaging: 99 subjects 
t = 36 Video consensus: 99 
subjects 
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Table 6-1 Baseline demographic and clinical data for 99 subjects with [1231] FP-
CIT SPECT according to the consensus video diagnosis 
Consensus video diagnosis at t = 36 months 
Degenerative parkinsonism Non-degenerative 
n (%) parkinsonism 
n (%) 
Probable PO Possible PO 
66 (66.7) 5 (5.1) 28 (28.3) 
Age (years) 61 (10) 69 (9) 59 (12) 
Sex Male (%) 57 (56%) 2 (40%) 19 (68%) 
Height (cm) 167 (9) 165 (12) 170 (9) 
Weight (kg) 72 (14) 66 (13) 79 (14) 
H & Y score (n, %) 
1 31 (47) 3 (60) 13 (46) 
1.5 8 (12) 0(0) 1 (4) 
2 21 (32) 2 (40) 13 (46) 
2.5 4 (6) 0(0) 1 (4) 
3 2 (3) 0(0) 0(0) 
UPDRS motor t = 0 11 (4) 12 (2) 6 (4) 
Symptom duration 2 (1.5) 4 (1) 3 (3) 
(years) 
SPECT result at t = 0 
Abnormal 56 (85%) 0(0%) 1 (4%) 
Normal 10(15%) 5 (100%) 27 (96%) 
History of alcohol 4 (6%) 0(0%) 2 (7%) 
response (%) 
Family history of 17 (26%) 4 (80%) 15 (54%) 
tremor disorder (%) 
Data are mean (SO) unless otherwise specified 
UPDRS = Unified Parkinson's Disease Rating Scale, H & Y = modified Hoehn and 
Yahr score 
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Table 6-2 Motor scoring and antiparkinson medication use at t = 0 and 36 
months according to consensus video diagnosis 
Probable PO Possible PO Non-PO 
n = 66 n=5 n = 28 
t = 0 t = 36 t= 0 t= 36 t = 0 
UPORS 11 (4) 21 (11) 12 (2) 12 (4) 6 (4) 
H&Y 1.5 (0.6) 2.2 (0.7) 1.4 (0.5) 1.6 (0.5) 1.6 (0.5) 
Antiparkinson 35 (53%) 53 (80%) 1 (20%) 1 (20%) 1 (4%) 
medication 
L-dopa 16 (24%) 33 (50%) 0(0%) 1 (20%) 0(0%) 
Table 6-3 Motor scoring and anti parkinson medication use at t = 0 and 36 
months according to baseline visual assessment of [1231] FP-CIT SPECT 
Baseline [1231] FP-CIT SPECT result 
Abnormal Normal 
n = 57 n =42 
t = 0 t = 36 t = 0 t = 36 
UPORS 11 (4) 21 (11) 8 (5) 10 (8) 
H&Y 1.5 (0.6) 2.1 (0.7) 1.5 (0.5) 1.8 (0.8) 
Antiparkinson 32 (56%) 49 (86%) 5(11%) 6 (14%) 
medication 
L-dopa 14 (25%) 30 (53%) 2 (5%) 4 (10%) 
t= 36 
7 (5) 
1.7 (0.8) 
1 (4%) 
0(0%) 
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Table 6-4 Change in motor UPDRS and anti parkinson medication use 
according to consensus video diagnosis and baseline visual assessment of 
[1231] FP-CIT SPECT 
UPORS motor 
change (SO) 
Increase in 
number of 
subjects on 
anti parkinson 
medication (%) 
According to gold-standard video consensus diagnosis at t = 36 months 
Probable PO n = 66 +10.0 (10.6)*** 
(SPECT 56 abnormal: 10 
normal scans) 
Possible PO n = 5 0.0 (5.4)ns 
(SPECT 5 normal scans) 
Non-PO n = 28 +0.7 (4.1) ns 
(SPECT 27 normal: 1 
abnormal scan) 
According to baseline imaging result 
Abnormal n = 57 +10.2 (10.5) *** 
Normal n = 42 +2.3 (7.0) * 
+27.0% 
0.0% 
0.0% 
+30.0% 
+2.0% 
Increase in 
number of 
subjects on L-
dopa (%) 
+26.0% 
0.0% 
+28.0% 
+5.0% 
Data are mean (SO) unless otherwise stated. All changes are over 3 year study 
period. UPORS = Unified Parkinson's Disease Rating Scale; t = time from study entry 
*** = p < 0.0001, * = P < 0.05, ns = not significant p > 0.05 
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Table 6-5 Diagnostic sensitivity, specificity, predictive values and accuracy of 
clinical and imaging diagnoses compared to the 3 year consensus video 
diagnosis 
time Diagnosis Sensitivity Specificity PPV NPV Accuracy 
(months) method 
t= 0 On-site 93 (84-98) 46 (27-66) 81 72 80 
clinical 
diagnosis 
On-site 80 (69-89) 90 (74-98) 95 67 83 
SPEeT 
read 
Independent 77.5 - 78.5 96.6 98 65 - 67 83 - 84 
SPEeT 
read* 
t=18 Independent 77.5 - 81.5 92.9 - 96.4 
SPEeT 
read* 
t = 36 Independent 75 - 77.9 96.3 
SPEeT 
read* 
Data are % (95% confidence interval). *Values for independent SPEeT readings are 
ranges as values were calculated separately for each of 3 readers. t = time from 
study entry, PPV = positive predictive value, NPV = negative predictive value. 
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Table 6-6 Consensus video diagnosis versus baseline on-site diagnosis and 
baseline visual assessment of [1231] FP-CIT SPECT 
Probable PO Possible PO Benign Non-PO 
t = 0 tremulous PO 
On-site diagnosis 44 31 6 18 
/~~ /~~ / ~ /~~ 
Prob Poss Non- Prob Poss Non- Prob Poss Prob Poss Non-
t = 36 PO PO PO PO PO PO PO PO PO PO PO 
'Gold standard' video diagnosis 
38 2 4 19 1 11 5 1 4 1 13 
(86%) (5%) (9%) (61%) (3%) (36%) (83%) (17%) (22%) (6%) (72%) 
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ 
SPEeT t = 0 35:3 0:2 0:4 16:3 0:1 1 :10 3:2 0:1 2:2 0:1 0:13 
Abnormal: normal 
t = time in months from study entry 
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Chapter 7 : Discussion and interpretation 
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Discussion 
Although the development of diagnostic dopamine transporter imaging showed high 
accuracy in differentiating patients fulfilling criteria for Parkinson's disease from those 
with essential tremor(161; 162), the application of this technique in routine clinical 
practice requires a different analysis. The comparative utility of SPECT imaging to 
differentiate between degenerative parkinsonism and other mimics such as drug-
induced parkinsonism or vascular parkinsonism are additional diagnostic pairings 
which are of clinical importance. The meaning of a normal SPECT(214) is one of the 
most important areas under debate and relates to the clinical features and the final 
diagnosis of subjects with a PD diagnosis but unexpected normal dopaminergic 
imaging, a field where little information is available. The lack of large blinded long-
term clinical assessments of dopamine transporter imaging in early and uncertain 
parkinsonism has received criticism(218), as it is often early in the disease course 
when there is the most clinical uncertainty. 
The main aims of this research were therefore: 
1) To further the understanding of the current clinical use of dopamine 
transporter imaging in uncertain parkinsonian disorders, and in particular to 
provide information on trends of imaging use, diagnosis and scan mismatch 
or misdiagnosis between different diagnostic pairings, with reference to the 
clinical features in 190 subjects in the multicentre UK Case Collection study 
(Chapters 2, 3 and 4), 
2) Clarification of the meaning of normal dopamine transporter imaging in the 
context of clinical uncertainty between degenerative parkinsonism and a non-
degenerative mimic. Evidence is derived to answer this question from the 3 
year follow-up of 150 consecutive subjects with normal C231] FP-CIT SPECT 
and more specifically, follow-up of antiparkinson therapy withdrawal in 11 
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subjects who fulfilled criteria for parkinsonism (Chapter 5), together with the 
assessment of precision of baseline SPECT imaging in a large long-duration 
blinded prospective European-wide study of 99 subjects with uncertain 
parkinsonian conditions (Chapter 6). 
3) To obtain facts to add to the few available, on the clinical and imaging 
characteristics of subjects with scans without evidence of dopaminergic deficit 
(SWEDD's) who have a diagnosis of Parkinson's disease, which has been 
accomplished through follow-up and withdrawal of anti parkinson medication 
in 11 patients (Chapter 5) and through the blinded European-wide study in 99 
subjects with uncertain parkinsonism (Chapter 6). 
A number of features make this work unique: 
Whilst there have been a number of contributions from the literature on the utility of 
dopamine transporter imaging in routine clinical practice(122;186;281), few have 
been prospective assessments, nor on such a large scale such as the UK Case 
Collection (Chapters 2, 3 and 4). Neither do they focus on the diagnostic sub-
groupings to allow inter-group comparisons of scant diagnosis mismatch rates which 
can potentially raise clinicians' awareness of difficult diagnostic areas and fuel future 
research. 
We provide the first ever account of the follow-up of 150 subjects with normal SPECT 
and of a smaller but more specifically defined group with anti parkinson therapy 
withdrawal (Chapter 5) which has not been described before in the literature. 
The European-wide blinded prospective study of C231] FP-CIT SPECT in early 
parkinsonism and tremor disorders (Chapter 6) is unique because of its scale, and 
because the gold-standard diagnosis was made 3 years after presentation (which is 
2 years longer than that of the only previous blinded study in uncertain 
parkinsonism(164)), which potentially allows for a 'more accurate' gold standard 
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diagnosis. It is also the first study to use the video-rater diagnosis as a gold standard 
in this context. 
The main contributions of this thesis are therefore directed toward advancing the 
understanding of the diagnostic utility of dopamine transporter imaging in early and 
uncertain parkinsonian tremor disorders within routine clinical practice and within the 
blinded trial setting and are summarised as follows: 
The use of dopamine transporter imaging in routine clinical practice in 
uncertain parkinsonian syndromes 
The UK Case Collection Study reflects the use of dopamine transporter imaging in 
routine clinical practice. The initial tentative clinical diagnosis was incorrect in a 
quarter of cases according to the post-scan revised diagnosis (mismatch) which is 
influenced by knowledge of theSPECT result. A third of patients considered to have 
degenerative parkinsonism had normal imaging (only 2% had a diagnosis of 
degenerative parkinsonism post-scan) and a quarter suspected to have non-
degenerative parkinsonism had abnormal imaging. Patterns of higher mismatch rate 
were identified for a pre-scan diagnosis of vascular parkinsonism which was incorrect 
in nearly a half, and unexpected abnormal imaging was found in a parkinsonian 
distribution (not a focal reduction pattern). Additionally, a higher rate of diagnostic 
change after imaging occurred when parkinsonism was associated with dementia or 
dystonia. A large proportion (43%) fulfilling Brain Bank Criteria part 1 (bradykinesia 
plus at least one of tremor, rigidity or postural instability) had normal scans. This 
figure may appear high, but it must be realised that patients were selected for 
diagnostic uncertainty regarding the presence or absence of parkinsonism, and that 
fulfilment of other Brain Bank criteria was not required. Nevertheless, this is a 
representative proportion of cases with uncertain parkinsonism in the clinical practice 
of UK movement disorder experts. 
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SPEeT by visual assessment was usually either clearly abnormal or normal, with a 
few cases (3%) of abnormal/ borderline results which were clearly not helpful in 
aiding the diagnostic decision. 
An assessment of the clinical features of diagnostic pairing between degenerative 
parkinsonism and essential tremor, identified rarer clinical presentations such as 
prominent asymmetrical postural tremor without rest tremor occurring in degenerative 
parkinsonism(21) and normal scans occurring in the context of definite rest tremor 
without a postural component (in which the post-scan diagnosis was a benign tremor 
disorder), and asymmetrical tremor was a common feature in patients with ET. 
Within the diagnostic pairing of degenerative parkinsonism and drug-induced 
parkinsonism there are a number of interesting clinical and imaging findings. 
Asymmetry and rest tremor were often documented in patients with drug-induced 
parkinsonism, which adds to the current evidence that DIP can present identically to 
PD(65). A proportion of patients with DIP did not improve or only partially improved 
after the follow-up time-period, suggesting either dual pathology, or that clinical 
improvement may sometimes be considerably delayed after withdrawal of drugs 
which cause DIP. As well as the usual dopamine depleting culprits, we identified 9 
subjects with DIP where valproate was used. This complements the recent 
identification of valproate induced parkinsonism(255). 
Additionally in this drug-induced diagnostic pairing, we identified 2 with borderline 
normal imaging results, which is of great interest considering the potential for patients 
with subclinical Parkinson's disease (where the dopaminergic imaging might still be 
normal) to be unmasked by the post-synaptic blockade effect of dopamine-depletors, 
resulting in a near-normal scan. This scenario has already been highlighted(219), 
and here we identified patients at risk of this but so far without evidence of imaging 
progression and clinical progression after drug withdrawal. 
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The meaning of normal dopamine transporter imaging 
Nearly all of the 150 patients (Chapter 5) who had normal [1231] FP-CIT SPECT had 
final diagnoses of non-degenerative parkinsonism or benign tremor disorders (mostly 
essential tremor), despite a most likely pre-scan diagnosis of degenerative 
parkinsonism in half of them, and antiparkinson medication use in one third. The lack 
of clinical progression and lack of response to antiparkinson medication (in those 
who used it) is not in keeping with emerging degenerative parkinsonism. Uncertain 
(and non-classifiable) parkinsonism occurs in around 5% of consecutive parkinsonian 
cases attending specialist clinics, and in our study a proportion of patients had non-
classifiable disorders which were considered to be non-degenerative in origin in 
most, although in 4 a diagnosis of degenerative parkinsonism (although uncertain) 
remained. This was despite repeat normal imaging in 2 subjects. 
More specifically, we reviewed 11 patients with normal SPECT who fulfilled Brain 
Bank criteria· and were on antiparkinson medication, many of whom could have been 
considered for entry into studies with PD. Medication was stopped without 
deterioration and diagnoses were revised away from degenerative parkinsonism -
mostly to essential tremor, because of a combination of knowledge of the imaging 
result and emergence of clinical features which argued against PD. These patients 
had symptom duration of 5.6 years prior to SPECT and follow-up for a further 3 
years. We consider these patients similar to SWEDD's and withdrawal of medication 
in these patients - successful or otherwise - has not been reported previously. This 
series is therefore instructive to the movement disorder community, in that 
misdiagnoses of non-degenerative parkinsonism! benign tremor disorders do occur, 
even in the context of the fulfilment of Brain Bank criteria (all 3 criteria continued to 
be fulfilled in 3 of 11 subjects). 
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Sensitivity and specificity of [1231] FP-CIT SPECT in early and uncertain 
parkinsonian disorders 
In the European-wide study of early parkinsonism/ tremor disorders, there are a 
number of interesting observations. 
When considering the primary study objective, the sensitivity of the baseline imaging 
was around 78% and specificity was very high at 97%. However, the on-site baseline 
clinical diagnosis over-diagnosed PD according to the 3 year gold standard 
diagnosis. This means that the baseline imaging has a higher positive predictive 
value than a baseline clinical diagnosis, but a lower negative predictive value. That 
is, according to this gold-standard a baseline SPECT can rule in degenerative 
parkinsonism but it cannot rule it out. The reasons for this poorer sensitivity have 
been considered in depth in Chapter 6. These sensitivity results are lower than those 
reported in a smaller blinded prospective study of dopamine transporter imaging(208) 
which is surprising. When comparing this group of SWEDD's (subjects with scans 
without evidence of dopaminergic deficit) to those with a PD diagnosis and evidence 
of dopaminergic deficiency, there are important differences. The cases reported here 
displayed no significant change in motor rating scales over 3 years, and around half 
of SWEDD's remained off PD medication, suggesting a different rate of clinical 
deterioration than is seen in true idiopathic PD. There was additional evidence that 
such patients are a difficult group to diagnose; there was higher video-rater 
disagreement between a degenerative parkinsonism versus non-degenerative 
diagnosis, and lower confidence in diagnosis in the SWEDD's. Additionally in half of 
the SWEDD cases the on-site clinician disagreed with a diagnosis of degenerative 
parkinsonism (although they were aware of SPECT result which may have biased 
them towards this). 
Importantly, repeated imaging in the SWEDD group remained normal in virtually all 
cases. One subject had imaging which changed from normal to abnormal. This 
subject was rated by one video-rater at each time point as having either multiple 
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system atrophy or vascular parkinsonism and we have discussed in Chapter 6 the 
possibility of the rare occurrence of minimal change MSA(280) or CBD(181), where 
the scan might be normal or borderline. We have not found evidence that this 
scenario occurs more than rarely. Over the 3 year monitoring period, most SWEDD's 
have a lack of clinical progression and a different antiparkinson therapy requirement 
and an imaging course which is out of keeping with that expected in degenerative 
parkinsonism. 
Limitations 
The unblinded nature of the UK multicentre case collection leads to a potentially 
circular argument of the utility of imaging and misdiagnosis rates based on the 
clinician's belief of the accuracy, and especially the sensitivity of dopamine 
transporter imaging. However, this particular study relates to day-to-day application 
of dopamine transporter imaging and its influence in routine clinical practice, rather 
than its 'correctness'. Also it is unlikely that a clinician would be comfortable changing 
from a degenerative parkinsonism diagnosis if clinical deterioration were apparent in 
keeping with degenerative parkinsonism, nor would we expect it would deter a trial of 
antiparkinson therapy in such a setting. This is supported by the evidence that over 3 
years the vast majority of patients with normal imaging did not deteriorate or 
experience anti parkinson medication benefit which would be in keeping with an 
emerging degenerative parkinsonian diagnosis. 
Conclusion 
In routine clinical practice, one quarter of patients with uncertain parkinsonism 
undergoing [1231] FP-CIT SPECT initially have an incorrect clinical diagnosis. 
Diagnostic change occurred in the vast majority of cases in line with the scan result, 
which is demonstrative of the considerable influence of dopamine transporter 
imaging. 
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A substantial proportion of patients who fulfil basic criteria (Brain Bank part 1) for 
Parkinson's disease actually have normal dopamine transporter imaging. Prolonged 
follow-up of these subjects identifies a lack of clinical progression, and a poor 
antiparkinson therapy response which is not in keeping with emerging degenerative 
parkinsonism. Additionally patients initially considered to have a PO diagnosis with 
fulfilment of PO criteria, but with normal SPECT are able to successfully stop 
antiparkinson therapy without deterioration. 
Parkinson's disease is clinically over-diagnosed at an early stage, and clinicians 
might benefit from the superior ability of early SPECT to 'rule in' degenerative 
parkinsonism. Subjects with a gold standard of degenerative parkinsonism but 
normal SPECT follow a different clinical and imaging course to those with evidence 
of dopaminergic deficit on imaging. 
If SPECT imaging is normal in the case of a patient with parkinsonism, this is a major 
indication that the patient suffers from a non-degenerative parkinsonian condition. 
Subsequent to this, unless we can be certain that these subjects definitely have PO 
(and we provide evidence to the contrary), it would be pertinent to use functional 
dopaminergic imaging as a adjunctive tool to ensure that in the trial setting, therapy is 
not tested on patients with normal imaging whom we have shown to have a different 
clinical progression and antiparkinson medication requirement and response to those 
with a confirmed PO diagnosis. 
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